BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-8. [PMID: 25512453 DOI: 10.1200/JCO.2014.57.9151] [Cited by in Crossref: 802] [Cited by in F6Publishing: 406] [Article Influence: 100.3] [Reference Citation Analysis]
Number Citing Articles
1 Granito A, Facciorusso A, Sacco R, Bartalena L, Mosconi C, Cea UV, Cappelli A, Antonino M, Modestino F, Brandi N, Tovoli F, Piscaglia F, Golfieri R, Renzulli M. TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. J Pers Med 2021;11:1041. [PMID: 34683182 DOI: 10.3390/jpm11101041] [Reference Citation Analysis]
2 Odagiri N, Hai H, Thuy LTT, Dong MP, Suoh M, Kotani K, Hagihara A, Uchida-Kobayashi S, Tamori A, Enomoto M, Kawada N. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. Cancers (Basel) 2020;12:E2045. [PMID: 32722224 DOI: 10.3390/cancers12082045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Kudo M. Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm. Liver Cancer 2017;6:185-8. [PMID: 28626730 DOI: 10.1159/000462199] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Zamora-Valdes D, Taner T, Nagorney DM. Surgical Treatment of Hepatocellular Carcinoma. Cancer Control 2017;24:1073274817729258. [PMID: 28975836 DOI: 10.1177/1073274817729258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
5 Ito T, Ishigami M, Morooka H, Yamamoto K, Imai N, Ishizu Y, Honda T, Nishimura D, Tada T, Yasuda S, Toyoda H, Kumada T, Fujishiro M. The albumin-bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC. Sci Rep 2020;10:17812. [PMID: 33082429 DOI: 10.1038/s41598-020-74732-3] [Reference Citation Analysis]
6 Kanda M, Tanaka C, Kobayashi D, Uda H, Inaoka K, Tanaka Y, Hayashi M, Iwata N, Yamada S, Fujii T, Sugimoto H, Murotani K, Fujiwara M, Kodera Y. Preoperative Albumin-Bilirubin Grade Predicts Recurrences After Radical Gastrectomy in Patients with pT2-4 Gastric Cancer. World J Surg 2018;42:773-81. [PMID: 28920160 DOI: 10.1007/s00268-017-4234-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
7 Yang Z, Zou R, Zheng Y, Qiu J, Shen J, Liao Y, Zhang Y, Wang C, Wang Y, Yuan Y, Li K, Zuo D, He W, Liu W, Li B, Yuan Y. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. Eur Radiol 2019;29:5752-62. [PMID: 30993438 DOI: 10.1007/s00330-019-06157-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
8 Zhang F, Lu S, Tian M, Hu K, Chen R, Zhang B, Ren Z, Shi Y, Yin X. Albumin-to-Alkaline Phosphatase Ratio is an Independent Prognostic Indicator in Combined Hepatocellular and Cholangiocarcinoma. J Cancer 2020;11:5177-86. [PMID: 32742464 DOI: 10.7150/jca.45633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Katayama K. Clinical significance of the latency period of abnormal ammonia metabolism in chronic liver disease: Proposal of a new concept. Hepatol Res 2021. [PMID: 34679199 DOI: 10.1111/hepr.13724] [Reference Citation Analysis]
10 Tajiri K, Futsukaichi Y, Kobayashi S, Nagata K, Yasumura S, Takahara T, Minemura M, Yasuda I. Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2019;12:2205-14. [PMID: 30988625 DOI: 10.2147/OTT.S191741] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Fukushima T, Morimoto M, Kobayashi S, Ueno M, Sano Y, Kawano K, Asama H, Nagashima S, Maeda S. Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. Mol Clin Oncol 2021;14:119. [PMID: 33903825 DOI: 10.3892/mco.2021.2281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Safcak D, Drazilova S, Gazda J, Andrasina I, Adamcova-Selcanova S, Barila R, Mego M, Rac M, Skladany L, Zigrai M, Janicko M, Jarcuska P. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival-A Retrospective Analysis of a Slovak Cohort. J Clin Med 2021;10:3186. [PMID: 34300352 DOI: 10.3390/jcm10143186] [Reference Citation Analysis]
13 Elhence A, Shalimar. Liver dysfunction in Barcelona Clinic Liver Cancer-2022 update: clear as day or still in fog? J Hepatol 2021:S0168-8278(21)02291-1. [PMID: 34954248 DOI: 10.1016/j.jhep.2021.12.016] [Reference Citation Analysis]
14 Jing CY, Fu YP, Huang JL, Zhang MX, Yi Y, Gan W, Xu X, Shen HJ, Lin JJ, Zheng SS, Zhang J, Zhou J, Fan J, Ren ZG, Qiu SJ, Zhang BH. Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic Cholangiocarcinoma. Oncologist 2018;23:1482-93. [PMID: 30257891 DOI: 10.1634/theoncologist.2017-0439] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
15 Ohashi K, Ishikawa T, Hoshi A, Suzuki M, Mitobe Y, Yamada E, Abeywickrama HM, Seki N, Koyama C, Aoki H, Koyama Y. Relationship Between Sarcopenia and Both Physical Activity and Lifestyle in Patients With Chronic Liver Disease. J Clin Med Res 2018;10:920-7. [PMID: 30425765 DOI: 10.14740/jocmr3640] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
16 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Lee YH, Huang YH, Lee FY, Hou MC, Huo TI. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep. 2018;8:4773. [PMID: 29555927 DOI: 10.1038/s41598-018-22923-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
17 Bettinger D, Spode R, Glaser N, Buettner N, Boettler T, Neumann-Haefelin C, Brunner TB, Gkika E, Maruschke L, Thimme R, Schultheiss M. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. BMC Gastroenterol 2017;17:98. [PMID: 28797231 DOI: 10.1186/s12876-017-0656-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
18 Zhang ZQ, Xiong L, Zhou JJ, Miao XY, Li QL, Wen Y, Zou H. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC. World J Surg Oncol. 2018;16:208. [PMID: 30326907 DOI: 10.1186/s12957-018-1500-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
19 Hamada M, Ueshima E, Ishihara T, Koide Y, Okada T, Horinouchi H, Ishida J, Mayahara H, Sasaki K, Gentsu T, Sofue K, Yamaguchi M, Sasaki R, Sugimoto K, Murakami T. The feasibility of transcatheter arterial chemoembolization following radiation therapy for hepatocellular carcinoma. Acta Radiol Open 2021;10:20584601211034965. [PMID: 34394958 DOI: 10.1177/20584601211034965] [Reference Citation Analysis]
20 Fujita K, Masaki T. Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept "Compensated Advanced Chronic Liver Disease". J Clin Med 2021;10:3340. [PMID: 34362121 DOI: 10.3390/jcm10153340] [Reference Citation Analysis]
21 Chen GX, Qi CY, Hu WJ, Wang XH, Hua YP, Kuang M, Peng BG, Li SQ. Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma. BMC Cancer 2020;20:487. [PMID: 32471389 DOI: 10.1186/s12885-020-06980-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Mak LY, Hui RW, Fung J, Liu F, Wong DK, Li B, Cheung KS, Yuen MF, Seto WK. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int 2021;15:901-11. [PMID: 34152534 DOI: 10.1007/s12072-021-10218-2] [Reference Citation Analysis]
23 Kendall TJ, Dolman GE, Duff CM, Paish EC, Zaitoun A, Irving W, Fallowfield JA, Guha IN. Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease. Histopathology 2018;73:90-100. [PMID: 29464815 DOI: 10.1111/his.13499] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
24 Shah RM, Sheikh S, Shah J, Vivian E, Mejia A, Shahin I, Mantry PS. Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center. J Gastrointest Oncol 2021;12:1718-31. [PMID: 34532122 DOI: 10.21037/jgo-20-435] [Reference Citation Analysis]
25 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
26 Li Z, Hu Y, Zeng Q, Wang H, Yan J, Li H, Yu Z. Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p. Cancer Cell Int 2019;19:211. [PMID: 31413665 DOI: 10.1186/s12935-019-0926-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
27 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. BMC Cancer 2017;17:279. [PMID: 28420329 DOI: 10.1186/s12885-017-3267-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
28 Mullikin TC, Pepin KM, Evans JE, Venkatesh SK, Ehman RL, Merrell KW, Haddock MG, Harmsen WS, Herman MG, Hallemeier CL. Evaluation of Pretreatment Magnetic Resonance Elastography for the Prediction of Radiation-Induced Liver Disease. Adv Radiat Oncol 2021;6:100793. [PMID: 34820550 DOI: 10.1016/j.adro.2021.100793] [Reference Citation Analysis]
29 Legaz I, Bolarin JM, Campillo JA, Moya RM, Luna A, Osuna E, Minguela A, Sanchez-Bueno F, Alvarez MR, Muro M. Pretransplant ascites and encephalopathy and their influence on survival and liver graft rejection in alcoholic cirrhosis disease. Arch Med Sci 2021;17:682-93. [PMID: 34025838 DOI: 10.5114/aoms.2018.80651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 O’Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol 2018; 24(39): 4436-4447 [PMID: 30357021 DOI: 10.3748/wjg.v24.i39.4436] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
31 Lee PC, Chao Y, Chen MH, Lan KH, Lee CJ, Lee IC, Chen SC, Hou MC, Huang YH. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E182. [PMID: 31940757 DOI: 10.3390/cancers12010182] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
32 Lin K, Huang Q, Wang L, Zeng J, Ding Z, Liu H, Fu J, Guo P, Chen Z, Zeng Y, Zhou W, Liu J. Pre- and Postoperative Models for Prediction of Recurrence in Non-B, Non-C Hepatocellular Carcinoma. Front Oncol 2021;11:612588. [PMID: 33680963 DOI: 10.3389/fonc.2021.612588] [Reference Citation Analysis]
33 Wu Z, Wei C, Wang L, He L. Determining the Traditional Chinese Medicine (TCM) Syndrome with the Best Prognosis of HBV-Related HCC and Exploring the Related Mechanism Using Network Pharmacology. Evid Based Complement Alternat Med 2021;2021:9991533. [PMID: 34306165 DOI: 10.1155/2021/9991533] [Reference Citation Analysis]
34 Casellas-Robert M, Lim C, Lopez-Ben S, Lladó L, Salloum C, Codina-Font J, Comas-Cufí M, Ramos E, Figueras J, Azoulay D. Laparoscopic Liver Resection for Hepatocellular Carcinoma in Child-Pugh A Patients With and Without Portal Hypertension: A Multicentre Study. World J Surg 2020;44:3915-22. [PMID: 32661688 DOI: 10.1007/s00268-020-05687-9] [Reference Citation Analysis]
35 Sato M, Morimoto K, Kajihara S, Tateishi R, Shiina S, Koike K, Yatomi Y. Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Sci Rep. 2019;9:7704. [PMID: 31147560 DOI: 10.1038/s41598-019-44022-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
36 Dai HT, Chen B, Tang KY, Zhang GY, Wen CY, Xiang XH, Yang JY, Guo Y, Lin R, Huang YH. Prognostic value of splenic volume in hepatocellular carcinoma patients receiving transarterial chemoembolization. J Gastrointest Oncol 2021;12:1141-51. [PMID: 34295563 DOI: 10.21037/jgo-21-226] [Reference Citation Analysis]
37 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Hsia CY, Lee RC, Hou MC, Huo TI. ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. J Gastrointest Oncol 2021;12:722-34. [PMID: 34012661 DOI: 10.21037/jgo-20-332] [Reference Citation Analysis]
38 Fragaki M, Sifaki-Pistolla D, Orfanoudaki E, Kouroumalis E. Comparative evaluation of ALBI, MELD, and Child-Pugh scores in prognosis of cirrhosis: is ALBI the new alternative? Ann Gastroenterol 2019;32:626-32. [PMID: 31700241 DOI: 10.20524/aog.2019.0417] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Lescure C, Estrade F, Pedrono M, Campillo-Gimenez B, Le Sourd S, Pracht M, Palard X, Bourien H, Muzellec L, Uguen T, Rolland Y, Garin E, Edeline J. ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3794. [PMID: 34359695 DOI: 10.3390/cancers13153794] [Reference Citation Analysis]
40 Lin CY, Lin CC, Wang CC, Chen CL, Hu TH, Hung CH, Huang PY, Tsai MC. The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection. World J Surg. 2020;44:247-257. [PMID: 31559485 DOI: 10.1007/s00268-019-05197-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Marasco G, Colecchia A, Silva G, Rossini B, Eusebi LH, Ravaioli F, Dajti E, Alemanni LV, Colecchia L, Renzulli M, Golfieri R, Festi D. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol 2020; 26(24): 3326-3343 [PMID: 32655261 DOI: 10.3748/wjg.v26.i24.3326] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
42 Fujita K, Oura K, Yoneyama H, Shi T, Takuma K, Nakahara M, Tadokoro T, Nomura T, Morishita A, Tsutsui K, Himoto T, Masaki T. Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. Hepatol Res 2019;49:731-42. [PMID: 30892804 DOI: 10.1111/hepr.13333] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
43 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
44 Kumada T, Toyoda H, Yasuda S, Tada T, Tanaka J, Chayama K, Johnson PJ, Irving WL. Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus. Infect Dis Ther 2021;10:1001-13. [PMID: 33881712 DOI: 10.1007/s40121-021-00441-7] [Reference Citation Analysis]
45 Ochi H, Hiraoka A, Hirooka M, Koizumi Y, Amano M, Azemoto N, Watanabe T, Yoshida O, Tokumoto Y, Mashiba T, Yokota T, Abe M, Michitaka K, Hiasa Y, Joko K. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol 2021;56:90-100. [PMID: 33278003 DOI: 10.1007/s00535-020-01747-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 2020;7:117-31. [PMID: 32984089 DOI: 10.2147/JHC.S248314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Lei Q, Ao K, Zhang Y, Ma D, Ding D, Ke C, Chen Y, Luo J, Meng Z. Prognostic factors of the short-term outcomes of patients with hepatitis B virus-associated acute-on-chronic liver failure. Clinics (Sao Paulo). 2017;72:686-692. [PMID: 29236915 DOI: 10.6061/clinics/2017(11)07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
48 Mao S, Yu X, Shan Y, Fan R, Wu S, Lu C. Albumin-Bilirubin (ALBI) and Monocyte to Lymphocyte Ratio (MLR)-Based Nomogram Model to Predict Tumor Recurrence of AFP-Negative Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1355-65. [PMID: 34805014 DOI: 10.2147/JHC.S339707] [Reference Citation Analysis]
49 Lee PC, Chiou YY, Chiu NC, Chen PH, Liu CA, Kao WY, Huo TI, Huang YH, Hou MC, Lin HC, Wu JC, Su CW. Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. Sci Rep 2020;10:2006. [PMID: 32029840 DOI: 10.1038/s41598-020-58988-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
50 Tomonari T, Sato Y, Tanaka H, Tanaka T, Fujino Y, Mitsui Y, Hirao A, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Kagiwada H, Kitazawa M, Fukui K, Horimoto K, Takayama T. Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array. Oncotarget 2020;11:2531-42. [PMID: 32655838 DOI: 10.18632/oncotarget.27640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Shiba S, Shibuya K, Okamoto M, Okazaki S, Komatsu S, Kubota Y, Nakano T, Ohno T. Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma. Radiat Oncol 2020;15:195. [PMID: 32795340 DOI: 10.1186/s13014-020-01634-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Lacornerie T, Rio E, Mahé MA. [Stereotactic body radiation therapy for hepatic malignancies: Organs at risk, uncertainties margins, doses]. Cancer Radiother 2017;21:574-9. [PMID: 28844506 DOI: 10.1016/j.canrad.2017.07.028] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
53 Yan Y, Qiao L, Hua Y, Shao S, Zhang N, Wu M, Liu L, Zhou K, Liu X, Wang C. Predictive value of Albumin-Bilirubin grade for intravenous immunoglobulin resistance in a large cohort of patients with Kawasaki disease: a prospective study. Pediatr Rheumatol Online J 2021;19:147. [PMID: 34563210 DOI: 10.1186/s12969-021-00638-7] [Reference Citation Analysis]
54 Harimoto N, Araki K, Muranushi R, Hoshino K, Yamanaka T, Hagiwara K, Ishii N, Tsukagoshi M, Watanabe A, Shirabe K. Significance of zinc deficiency in patients with hepatocellular carcinoma undergoing hepatic resection. Hepatol Res 2021. [PMID: 34761491 DOI: 10.1111/hepr.13730] [Reference Citation Analysis]
55 Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC, Safran H, Bodoky G, Chau I, Shimada Y, Al-Batran SE, Passalacqua R, Ohtsu A, Emig M, Ferry D, Chandrawansa K, Hsu Y, Sashegyi A, Liepa AM, Wilke H. Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. J Gastric Cancer 2017;17:132-44. [PMID: 28680718 DOI: 10.5230/jgc.2017.17.e16] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
56 Yu MQ, An TZ, Li JX, Chang DH, Zhang ZS, Xiao YD. Integrated Liver Inflammatory Score Predicts the Therapeutic Outcome of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. J Vasc Interv Radiol 2021;32:1194-202. [PMID: 33819601 DOI: 10.1016/j.jvir.2021.03.540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Tada T, Kumada T, Hiraoka A, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. Sci Rep 2021;11:14474. [PMID: 34262065 DOI: 10.1038/s41598-021-93794-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Lawitz E, Poordad F, Gutierrez JA, Beumont M, Beets G, Vandevoorde A, Remoortere PV, Luo D, Vijgen L, Eygen VV, Gamil M. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci Rep 2020;3:e145. [PMID: 32270053 DOI: 10.1002/hsr2.145] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Kariyama K, Nouso K, Hiraoka A, Wakuta A, Oonishi A, Kuzuya T, Toyoda H, Tada T, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kudo M, Kumada T. EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. Liver Cancer 2020;9:734-43. [PMID: 33442542 DOI: 10.1159/000508971] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
60 Ghamarnejad O, Khajeh E, Rezaei N, Afshari K, Adelian A, Nikdad M, Hoffmann K, Mehrabi A. Comparative Analysis of the Discriminatory Performance of Different Well-Known Risk Assessment Scores for Extended Hepatectomy. Sci Rep 2020;10:930. [PMID: 31969586 DOI: 10.1038/s41598-020-57748-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
61 Kaneko S, Kurosaki M, Joko K, Marusawa H, Kondo M, Kojima Y, Uchida Y, Kimura H, Tsuji K, Yagisawa H, Kusakabe A, Kobashi H, Akahane T, Tamaki N, Kirino S, Abe T, Yoshida H, Matsushita T, Hasebe C, Izumi N. Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. Sci Rep. 2020;10:13021. [PMID: 32747646 DOI: 10.1038/s41598-020-69522-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
62 Zhang YF, Ji H, Lu HW, Lu L, Wang L, Wang JL, Li YM. Postoperative survival analysis and prognostic nomogram model for patients with portal hypertension. World J Gastroenterol 2018; 24(39): 4499-4509 [PMID: 30356927 DOI: 10.3748/wjg.v24.i39.4499] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
63 Oh IS, Sinn DH, Kang TW, Lee MW, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Dig Dis Sci. 2017;62:3235-3242. [PMID: 28983724 DOI: 10.1007/s10620-017-4775-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
64 Fang Q, Yang R, Chen D, Fei R, Chen P, Deng K, Gao J, Liao W, Chen H. A Novel Nomogram to Predict Prolonged Survival After Hepatectomy in Repeat Recurrent Hepatocellular Carcinoma. Front Oncol 2021;11:646638. [PMID: 33842361 DOI: 10.3389/fonc.2021.646638] [Reference Citation Analysis]
65 Wang Z, Wang E, Bai W, Xia D, Ding R, Li J, Wang Q, Liu L, Sun J, Mu W, Zhao H, Pan X, Shao G, Zhu X, Yin G, Shi H, Wu J, Lin Z, Yang S, Liu J, Wang W, Zhu X, Lv Y, Li J, Chen H, Wang W, Li K, Yuan X, Yu T, Yuan J, Li X, Niu J, Yin Z, Xia J, Fan D, Han G. Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study. Liver Cancer 2020;9:308-25. [PMID: 32647633 DOI: 10.1159/000505692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Ng SSW, Jang GH, Kurland IJ, Qiu Y, Guha C, Dawson LA. Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy. EBioMedicine. 2020;59:102973. [PMID: 32891936 DOI: 10.1016/j.ebiom.2020.102973] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
67 Adhoute X, Pénaranda G, Raoul JL, Bronowicki JP, Anty R, Bourlière M. “Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort. World J Hepatol 2020; 12(8): 525-532 [PMID: 32952879 DOI: 10.4254/wjh.v12.i8.525] [Reference Citation Analysis]
68 Xu B, Li XL, Ye F, Zhu XD, Shen YH, Huang C, Zhou J, Fan J, Chen YJ, Sun HC. Development and Validation of a Nomogram Based on Perioperative Factors to Predict Post-hepatectomy Liver Failure. J Clin Transl Hepatol 2021;9:291-300. [PMID: 34221915 DOI: 10.14218/JCTH.2021.00013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Bao M, Zhu Q, Aji T, Wei S, Tuergan T, Ha X, Tulahong A, Hu X, Hu Y. Development of Models to Predict Postoperative Complications for Hepatitis B Virus-Related Hepatocellular Carcinoma. Front Oncol 2021;11:717826. [PMID: 34676160 DOI: 10.3389/fonc.2021.717826] [Reference Citation Analysis]
70 Tai K, Kuramitsu K, Kido M, Tanaka M, Komatsu S, Awazu M, Gon H, So S, Tsugawa D, Mukubo H, Terai S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T. Impact of Albumin-Bilirubin Score on Short- and Long-Term Survival After Living-Donor Liver Transplantation: A Retrospective Study. Transplant Proc 2020;52:910-9. [PMID: 32183990 DOI: 10.1016/j.transproceed.2020.01.020] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Sansone V, Tovoli F, Casadei-Gardini A, Di Costanzo GG, Magini G, Sacco R, Pressiani T, Trevisani F, Rimini M, Tortora R, Nardi E, Ielasi L, Piscaglia F, Granito A. Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. Clin Transl Gastroenterol 2021;12:e00286. [PMID: 33443944 DOI: 10.14309/ctg.0000000000000286] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
72 Ng SSW, Zhang H, Wang L, Citrin D, Dawson LA. Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity. NPJ Precis Oncol 2020;4:17. [PMID: 32695883 DOI: 10.1038/s41698-020-0124-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Matsuda T, Umeda Y, Matsuda T, Endo Y, Sato D, Kojima T, Sui K, Inagaki M, Ota T, Hioki M, Oishi M, Kimura M, Murata T, Ishido N, Yagi T, Fujiwara T. Preoperative prognostic nutritional index predicts postoperative infectious complications and oncological outcomes after hepatectomy in intrahepatic cholangiocarcinoma. BMC Cancer 2021;21:708. [PMID: 34130648 DOI: 10.1186/s12885-021-08424-0] [Reference Citation Analysis]
74 Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Ueno T, Tojima H, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. Cancers (Basel) 2020;12:E2906. [PMID: 33050527 DOI: 10.3390/cancers12102906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
75 Deng S, Solinas A, Calvisi DF. Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models. Front Oncol 2021;11:756672. [PMID: 34722310 DOI: 10.3389/fonc.2021.756672] [Reference Citation Analysis]
76 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Reference Citation Analysis]
77 Toyoda H, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, Tanaka J. Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. Hepatol Commun 2021;5:1290-9. [PMID: 34278176 DOI: 10.1002/hep4.1716] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Lee SK, Song MJ, Kim SH, Park M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. PLoS One 2019;14:e0216173. [PMID: 31048923 DOI: 10.1371/journal.pone.0216173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
79 Vogel A, Merle P, Verslype C, Finn RS, Zhu AX, Cheng AL, Chan SL, Yau T, Ryoo BY, Knox J, Daniele B, Qin S, Wei Z, Miteva Y, Malhotra U, Siegel AB, Kudo M. ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. Ther Adv Med Oncol 2021;13:17588359211039928. [PMID: 34616489 DOI: 10.1177/17588359211039928] [Reference Citation Analysis]
80 Hiraoka A, Onishi M, Koyama S, Kato M, Marui K, Murakami T, Onishi K, Adachi T, Matsuoka J, Ueki H, Yoshino T, Tsuruta M, Aibiki T, Okudaira T, Kuroda T, Iwasaki R, Suga Y, Miyata H, Ninomiya T, Hirooka M, Abe M, Matsuura B, Michitaka K, Hiasa Y. Factors Related to Sleeping Disorder Due to Pruritus in Patients with Chronic Liver Disease. Intern Med 2021;60:3195-203. [PMID: 34657905 DOI: 10.2169/internalmedicine.7129-21] [Reference Citation Analysis]
81 Hu K, Lu S, Li M, Zhang F, Tang B, Yuan J, Shan Y, Xu P, Chen R, Ren Z, Yin X. A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma. J Cancer. 2020;11:4589-4596. [PMID: 32489476 DOI: 10.7150/jca.44847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Zhou PY, Yang CP, Tang Z, Yi Y, Liu WR, Tian MX, Huang JL, Gan W, Jiang XF, Liu G, Wang H, Tao CY, Fang Y, Qu WF, Zhou C, Guan RY, Sun BY, Zhou YF, Song SS, Ding ZB, Peng YF, Dai Z, Zhou J, Fan J, Gong GZ, Shi YH, Qiu SJ. Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. Aging (Albany NY). 2019;11:11111-11123. [PMID: 31829979 DOI: 10.18632/aging.102513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
83 Nishikawa H, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Sarcopenia and Frailty in Liver Cirrhosis. Life (Basel) 2021;11:399. [PMID: 33925660 DOI: 10.3390/life11050399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
84 Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, Mara KC, Harmsen WS, Theobald JP, Peters BE, Balsanek JG, Ward MM, Giama NH, Venkatesh SK, Harnois DM, Charlton MR, Yamada H, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol 2018; 24(12): 1321-1331 [PMID: 29599607 DOI: 10.3748/wjg.v24.i12.1321] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
85 Voutila J, Reebye V, Roberts TC, Protopapa P, Andrikakou P, Blakey DC, Habib R, Huber H, Saetrom P, Rossi JJ, Habib NA. Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer. Mol Ther 2017;25:2705-14. [PMID: 28882451 DOI: 10.1016/j.ymthe.2017.07.018] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
86 Hulin A, Stocco J, Bouattour M. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. Clin Pharmacokinet 2019;58:983-1014. [PMID: 31093928 DOI: 10.1007/s40262-019-00740-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
87 Hao F, Wang N, Wang X, Chen Y, Wang J. Identification of prognostic long non-coding RNA signature with potential drugs in hepatocellular carcinoma. Aging (Albany NY) 2021;13:18789-805. [PMID: 34285143 DOI: 10.18632/aging.203322] [Reference Citation Analysis]
88 Niizeki T, Iwamoto H, Shirono T, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Hiroyuki S, Sakai M, Kuromatsu R, Koga H, Torimura T. Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. Cancers (Basel) 2021;13:4450. [PMID: 34503259 DOI: 10.3390/cancers13174450] [Reference Citation Analysis]
89 Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
90 Wei CY, Chau GY, Chen PH, Liu CA, Huang YH, Huo TI, Hou MC, Lin HC, Su YH, Wu JC, Su CW. A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. Sci Rep 2020;10:17259. [PMID: 33057213 DOI: 10.1038/s41598-020-74424-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Tada T, Nishimura T, Matono T, Yoshida M, Yuri M, Fujiwara A, Yuri Y, Takashima T, Aizawa N, Ikeda N, Enomoto H, Kumada T, Iijima H. Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Hepatol Res 2021;51:860-9. [PMID: 34046970 DOI: 10.1111/hepr.13677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Ren W, Wu S, Wu Y, Liu T, Zhao X, Li Y. MicroRNA-196a/-196b regulate the progression of hepatocellular carcinoma through modulating the JAK/STAT pathway via targeting SOCS2. Cell Death Dis 2019;10:333. [PMID: 30988277 DOI: 10.1038/s41419-019-1530-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
93 Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel) 2020;12:E1862. [PMID: 32664319 DOI: 10.3390/cancers12071862] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
94 Scher N, Janoray G, Riet FG, Le Bayon AG, Debbi K, Lévy S, Louisot P, Garaud P, Chajon E, Barillot I, Salamé É, de Crevoisier R, Chapet S, Calais G. [Stereotactic body radiation therapy for hepatocellular carcinoma: Results from a retrospective multicentre study]. Cancer Radiother 2019;23:104-15. [PMID: 30952560 DOI: 10.1016/j.canrad.2018.07.138] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Wu Y, Tu C, Shao C. Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy. BMC Surg 2021;21:178. [PMID: 33794850 DOI: 10.1186/s12893-021-01180-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group., HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis. Hepatol Res 2021. [PMID: 34799975 DOI: 10.1111/hepr.13734] [Reference Citation Analysis]
97 Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C, Faloppi L, Rizzato MD, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F, Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astara G, Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS One 2020;15:e0232449. [PMID: 32379785 DOI: 10.1371/journal.pone.0232449] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
98 Li C, Zhang XY, Peng W, Wen TF, Yan LN, Li B, Yang JY, Wang WT, Xu MQ. Postoperative Albumin-Bilirubin Grade Change Predicts the Prognosis of Patients with Hepatitis B-Related Hepatocellular Carcinoma Within the Milan Criteria. World J Surg. 2018;42:1841-1847. [PMID: 29138913 DOI: 10.1007/s00268-017-4355-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
99 Vogel A, Frenette C, Sung M, Daniele B, Baron A, Chan SL, Blanc JF, Tamai T, Ren M, Lim HJ, Palmer DH, Takami Y, Kudo M. Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:510-21. [PMID: 34721512 DOI: 10.1159/000516490] [Reference Citation Analysis]
100 Villalobos A, Wagstaff W, Guo M, Zhang J, Bercu Z, Whitmore MJ, Cristescu MM, Majdalany BS, Wedd J, Akce M, Magliocca J, Kokabi N. Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:9926704. [PMID: 34336728 DOI: 10.1155/2021/9926704] [Reference Citation Analysis]
101 Chen Y, Liu Z, Mo Y, Li B, Zhou Q, Peng S, Li S, Kuang M. Prediction of Post-hepatectomy Liver Failure in Patients With Hepatocellular Carcinoma Based on Radiomics Using Gd-EOB-DTPA-Enhanced MRI: The Liver Failure Model. Front Oncol 2021;11:605296. [PMID: 33777748 DOI: 10.3389/fonc.2021.605296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Kyrochristos ID, Glantzounis GK, Ziogas DE, Gizas I, Schizas D, Lykoudis EG, Felekouras E, Machairas A, Katsios C, Liakakos T, Cho WC, Roukos DH. From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. Int J Mol Sci 2017;18:E180. [PMID: 28106782 DOI: 10.3390/ijms18010180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
103 Meriggi F, Graffeo M. Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers (Basel) 2021;13:584. [PMID: 33540870 DOI: 10.3390/cancers13030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Abu-Halima M, Meese E, Saleh MA, Keller A, Abdul-Khaliq H, Raedle-Hurst T. MicroRNA-29b/c-3p Indicate Advanced Liver Fibrosis/Cirrhosis in Univentricular Heart Patients With and Without Fontan Palliation. Front Cardiovasc Med 2020;7:619083. [PMID: 33490119 DOI: 10.3389/fcvm.2020.619083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
105 Morise Z. Laparoscopic liver resection for the patients with hepatocellular carcinoma and chronic liver disease. Transl Gastroenterol Hepatol 2018;3:41. [PMID: 30148226 DOI: 10.21037/tgh.2018.07.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
106 Ochi H, Tani J, Tomonari T, Taniguchi T, Koizumi Y, Hirose A, Ogawa C, Hiraoka A, Morishita A, Moriya A, Hirooka M, Deguchi A, Symple Study Group. Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis. Hepatol Res 2021;51:1219-28. [PMID: 34534398 DOI: 10.1111/hepr.13713] [Reference Citation Analysis]
107 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Nakano Y, Honda T, Yajima H, Uehara R, Miyazaki O, Kuribayashi Y, Kira K, Taura N, Nakao K. Comparison of calculated body muscle mass and SARC-F as methods of screening for sarcopenia in patients with chronic liver disease. Biomed Rep 2021;14:34. [PMID: 33732453 DOI: 10.3892/br.2021.1410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, Suzuki H, Niizeki T, Shirono T, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncol Lett 2020;20:2257-65. [PMID: 32782543 DOI: 10.3892/ol.2020.11758] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
109 Mai RY, Wang YY, Bai T, Chen J, Xiang BD, Wu GB, Wu FX, Li LQ, Ye JZ. Combination Of ALBI And APRI To Predict Post-Hepatectomy Liver Failure After Liver Resection For HBV-Related HCC Patients. Cancer Manag Res. 2019;11:8799-8806. [PMID: 31632139 DOI: 10.2147/cmar.s213432] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
110 Sainamthip P, Kongphanich C, Prasongsook N, Chirapongsathorn S. Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study. World J Clin Cases 2021; 9(30): 9059-9069 [PMID: 34786388 DOI: 10.12998/wjcc.v9.i30.9059] [Reference Citation Analysis]
111 Ni J, Fang Z, Sun H, An C, Huang Z, Zhang T, Jiang X, Chen Y, Xu L, Huang J. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. Eur Radiol 2020;30:2377-90. [DOI: 10.1007/s00330-019-06438-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
112 Shen J, Tang L, Zhang X, Peng W, Wen T, Li C, Yang J, Liu G. A Novel Index in Hepatocellular Carcinoma Patients After Curative Hepatectomy: Albumin to Gamma-Glutamyltransferase Ratio (AGR). Front Oncol 2019;9:817. [PMID: 31612101 DOI: 10.3389/fonc.2019.00817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
113 Feng D, Wang M, Hu J, Li S, Zhao S, Li H, Liu L. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. Ann Transl Med 2020;8:553. [PMID: 32411776 DOI: 10.21037/atm.2020.02.116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
114 Wang T, Yang X, Wang W, Chen T, Kong J, Shen S, Chen Y, Wei G, Yu D, Wang C, Li M, Rui S, Luo B, Wang W. A new sarcopenia score prognostic for postoperative complications in hepatic alveolar echinococcosis: a multicenter retrospective study. Ann Transl Med 2020;8:1398. [PMID: 33313143 DOI: 10.21037/atm-20-1960a] [Reference Citation Analysis]
115 Miyata T, Yamashita Y, Arima K, Higashi T, Hayashi H, Imai K, Nitta H, Chikamoto A, Beppu T, Baba H. Alteration of prognostic efficacy of albumin‐bilirubin grade and Child‐Pugh score according to liver fibrosis in hepatocellular carcinoma patients with Child‐Pugh A following hepatectomy. Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12498] [Reference Citation Analysis]
116 Luo HM, Zhao SZ, Li C, Chen LP. Preoperative platelet-albumin-bilirubin grades predict the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after liver resection: A retrospective study. Medicine (Baltimore). 2018;97:e0226. [PMID: 29561452 DOI: 10.1097/md.0000000000010226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
117 Palmer Kelly E, McGee J, Obeng-Gyasi S, Herbert C, Azap R, Abbas A, Pawlik TM. Marginalized patient identities and the patient-physician relationship in the cancer care context: a systematic scoping review. Support Care Cancer 2021. [PMID: 34195857 DOI: 10.1007/s00520-021-06382-8] [Reference Citation Analysis]
118 Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kasuya K, Sano T, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. Liver Cancer 2020;9:275-92. [PMID: 32647631 DOI: 10.1159/000505190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
119 Fernandez-Placencia R, Berrospi-Espinoza F, Uribe-Rivera K, Medina-Cana J, Chavez-Passiuri I, Sanchez-Bartra N, Paredes-Galvez K, Luque-Vasquez Vasquez C, Celis-Zapata J, Ruiz-Figueroa E. Preoperative Predictors for 90-Day Mortality after Pancreaticoduodenectomy in Patients with Adenocarcinoma of the Ampulla of Vater: A Single-Centre Retrospective Cohort Study. Surg Res Pract 2021;2021:6682935. [PMID: 33728373 DOI: 10.1155/2021/6682935] [Reference Citation Analysis]
120 Wang Z, Fan Q, Wang M, Wang E, Li H, Liu L. Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma. Ann Transl Med 2020;8:537. [PMID: 32411760 DOI: 10.21037/atm.2020.02.114] [Reference Citation Analysis]
121 Božin T, Mustapić S, Bokun T, Patrlj L, Rakić M, Aralica G, Kujundžić M, Trkulja V, Grgurević I. Albi Score as a Predictor of Survival in Patients with Compensated Cirrhosis Resected for Hepatocellular Carcinoma: Exploratory Evaluation in Relationship to Palbi and Meld Liver Function Scores. Acta Clin Croat 2018;57:292-300. [PMID: 30431722 DOI: 10.20471/acc.2018.57.02.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
122 Carr BI, Guerra V. Validation of a Liver Index and Its Significance for HCC Aggressiveness. J Gastrointest Cancer 2017;48:262-6. [PMID: 28631027 DOI: 10.1007/s12029-017-9971-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
123 Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, Torimura T. Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers (Basel) 2020;12:E1867. [PMID: 32664489 DOI: 10.3390/cancers12071867] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
124 Li L, Liu C, Yang J, Wu H, Wen T, Wang W, Li B, Yan L. Early postoperative controlling nutritional status (CONUT) score is associated with complication III-V after hepatectomy in hepatocellular carcinoma: A retrospective cohort study of 1,334 patients. Sci Rep 2018;8:13406. [PMID: 30194336 DOI: 10.1038/s41598-018-31714-w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
125 Yu JI, Park HC, Yoo GS, Choi C, Choi MS, Nam H, Baek SY, Park M. Clinical importance of the absolute count of neutrophils, lymphocytes, monocytes, and platelets in newly diagnosed hepatocellular carcinoma. Sci Rep 2021;11:2614. [PMID: 33510378 DOI: 10.1038/s41598-021-82177-5] [Reference Citation Analysis]
126 Ishikawa T, Imai M, Ko M, Sato H, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T, Yoshida T. Evaluation of the branched-chain amino acid-to-tyrosine ratio prior to treatment as a prognostic predictor in patients with liver cirrhosis. Oncotarget 2017;8:79480-90. [PMID: 29108327 DOI: 10.18632/oncotarget.18447] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
127 Mai RY, Zeng J, Mo YS, Liang R, Lin Y, Wu SS, Piao XM, Gao X, Wu GB, Li LQ, Ye JZ. Artificial Neural Network Model for Liver Cirrhosis Diagnosis in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Ther Clin Risk Manag 2020;16:639-49. [PMID: 32764948 DOI: 10.2147/TCRM.S257218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Yoshimaru D, Takatsu Y, Suzuki Y, Miyati T, Hamada Y, Funaki A, Tabata A, Maruyama C, Shimada M, Tobari M, Nishino T. Diffusion kurtosis imaging in the assessment of liver function: Its potential as an effective predictor of liver function. Br J Radiol 2019;92:20170608. [PMID: 30358410 DOI: 10.1259/bjr.20170608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
129 Poetter-Lang S, Staufer K, Baltzer P, Tamandl D, Muin D, Bastati N, Halilbasic E, Hodge JC, Trauner M, Kazemi-Shirazi L, Ba-Ssalamah A. The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. Eur Radiol 2019;29:1048-58. [PMID: 30054796 DOI: 10.1007/s00330-018-5650-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
130 Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwara A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T, On Behalf Of The Kurume Liver Cancer Study Group Of Japan. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers (Basel) 2021;13:2786. [PMID: 34205099 DOI: 10.3390/cancers13112786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
131 Sakamaki A, Yokoyama K, Koyama K, Morita S, Abe H, Kamimura K, Takamura M, Terai S. Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis. PLoS One 2020;15:e0242582. [PMID: 33201936 DOI: 10.1371/journal.pone.0242582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
132 Ding X, Sun W, Chen J, Li W, Shen Y, Guo X, Teng Y, Liu X, Sun S, Wei J, Li W, Chen H, Liu B. Percutaneous Radiofrequency Ablation Combined With Transarterial Chemoembolization Plus Sorafenib for Large Hepatocellular Carcinoma Invading the Portal Venous System: A Prospective Randomized Study. Front Oncol 2020;10:578633. [PMID: 33194699 DOI: 10.3389/fonc.2020.578633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
133 Tanaka T, Nishida H, Mie K, Yamazaki H, Lin LS, Akiyoshi H. Assessment of hepatitis and fibrosis using Gd-EOB-DTPA MRI in dogs. Vet Rec Open 2020;7:e000371. [PMID: 32818058 DOI: 10.1136/vetreco-2019-000371] [Reference Citation Analysis]
134 Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139-152. [PMID: 31792430 DOI: 10.1038/s41575-019-0229-4] [Cited by in Crossref: 104] [Cited by in F6Publishing: 115] [Article Influence: 34.7] [Reference Citation Analysis]
135 Zhang L, Sun JH, Hou ZH, Zhong BY, Yang MJ, Zhou GH, Wang WS, Huang P, Zhang S, Li Z, Zhu XL, Yan ZP, Ni CF. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. Cardiovasc Intervent Radiol 2021;44:63-72. [PMID: 32965582 DOI: 10.1007/s00270-020-02579-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Zhao S, Wang M, Yang Z, Tan K, Zheng D, Du X, Liu L. Comparison between Child-Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. Ann Transl Med 2020;8:539. [PMID: 32411762 DOI: 10.21037/atm.2020.02.85] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
137 Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol 2019;133:54-61. [PMID: 30935582 DOI: 10.1016/j.radonc.2018.10.041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
138 Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Okada M, Wang W, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One 2020;15:e0231828. [PMID: 32310967 DOI: 10.1371/journal.pone.0231828] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
139 Shinozaki S, Tahara T, Lefor AK, Ogura M. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease. Clin Exp Hepatol 2020;6:270-4. [PMID: 33145434 DOI: 10.5114/ceh.2020.99528] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
140 Wang S, Ding S, Luo H, Chai X. International Normalized Ratio to Albumin Ratio (PTAR): An Objective Risk Stratification Tool in Patients with Sepsis. Int J Gen Med 2021;14:1829-41. [PMID: 34012289 DOI: 10.2147/IJGM.S305085] [Reference Citation Analysis]
141 Xu YX, Wang YB, Tan YL, Xi C, Xu XZ. Prognostic value of pretreatment albumin to bilirubin ratio in patients with hepatocellular cancer: A meta-analysis. Medicine (Baltimore). 2019;98:e14027. [PMID: 30633195 DOI: 10.1097/md.0000000000014027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
142 Wan SZ, Nie Y, Zhang Y, Liu C, Zhu X. Assessing the Prognostic Performance of the Child-Pugh, Model for End-Stage Liver Disease, and Albumin-Bilirubin Scores in Patients with Decompensated Cirrhosis: A Large Asian Cohort from Gastroenterology Department. Dis Markers 2020;2020:5193028. [PMID: 32148566 DOI: 10.1155/2020/5193028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
143 Ke M, Xu T, Li N, Ren Y, Shi A, Lv Y, He H. Prognostic nutritional index predicts short-term outcomes after liver resection for hepatocellular carcinoma within the Milan criteria. Oncotarget 2016;7:81611-20. [PMID: 27835570 DOI: 10.18632/oncotarget.13151] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
144 Lee J, Cho Y, Park S, Kim JW, Lee IJ. Skeletal Muscle Depletion Predicts the Prognosis of Patients With Hepatocellular Carcinoma Treated With Radiotherapy. Front Oncol 2019;9:1075. [PMID: 31681607 DOI: 10.3389/fonc.2019.01075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
145 Sun J, Zhang T, Wang J, Li W, Zhang A, He W, Zhang D, Li D, Ding J, Duan X. Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm). BMC Cancer 2019;19:846. [PMID: 31455251 DOI: 10.1186/s12885-019-6063-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
146 Yin Y, Cheng JW, Chen FY, Chen XX, Zhang X, Huang A, Guo DZ, Wang YP, Cao Y, Fan J, Zhou J, Yang XR. A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma. Ann Transl Med 2021;9:774. [PMID: 34268387 DOI: 10.21037/atm-20-7842] [Reference Citation Analysis]
147 Trojan J. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs 2020;80:1203-10. [PMID: 32671719 DOI: 10.1007/s40265-020-01361-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
148 Chen G, Wang R, Zhang C, Gui L, Xue Y, Ren X, Li Z, Wang S, Zhang Z, Zhao J, Zhang H, Yao C, Wang J, Liu J. Integration of pre-surgical blood test results predict microvascular invasion risk in hepatocellular carcinoma. Comput Struct Biotechnol J 2021;19:826-34. [PMID: 33598098 DOI: 10.1016/j.csbj.2021.01.014] [Reference Citation Analysis]
149 Ohashi K, Ishikawa T, Hoshii A, Hokari T, Suzuki M, Mitobe Y, Yamada E, Abeywickrama HM, Kikuchi Y, Noguchi H, Hirosawa H, Koyama Y. Efficacy of Physical Activity in Prevention of Muscle Weakness in Patients With Chronic Liver Disease. J Clin Med Res 2019;11:711-9. [PMID: 31636786 DOI: 10.14740/jocmr3978] [Reference Citation Analysis]
150 Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol 2021;44:1851-67. [PMID: 34694454 DOI: 10.1007/s00270-021-02968-1] [Reference Citation Analysis]
151 Li Y, Chen G, Han Z, Cheng H, Qiao L, Li Y. IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells. Onco Targets Ther 2020;13:9721-30. [PMID: 33061451 DOI: 10.2147/OTT.S262089] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
152 Ho SY, Liu PH, Hsu CY, Chiou YY, Su CW, Lee YH, Huang YH, Lee FY, Hou MC, Huo TI. Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Sci Rep. 2018;8:843. [PMID: 29339752 DOI: 10.1038/s41598-018-19251-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
153 Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, Bae SH, Choi JY, Yoon SK. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol 2017;9:615-26. [PMID: 28974984 DOI: 10.1177/1758834017728018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
154 Yamamoto G, Taura K. Response to: Is ALPlat criterion justified for predicting posthepatectomy liver failure? Surgery 2020;168:1180-1. [PMID: 32981688 DOI: 10.1016/j.surg.2020.08.028] [Reference Citation Analysis]
155 Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Yang MJ, Zhou GH, Wang WS, Li Z, Huang P, Zhang S, Zhu XL, Ni CF. Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Oncol 2020;10:525461. [PMID: 33392064 DOI: 10.3389/fonc.2020.525461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
156 Personeni N, Pressiani T, D'Alessio A, Prete MG, Bozzarelli S, Terracciano L, Dal Buono A, Capogreco A, Aghemo A, Lleo A, Lutman RF, Roncalli M, Giordano L, Santoro A, Di Tommaso L, Rimassa L. Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:5665. [PMID: 34830823 DOI: 10.3390/cancers13225665] [Reference Citation Analysis]
157 Schipilliti FM, Garajová I, Rovesti G, Balsano R, Piacentini F, Dominici M, Gelsomino F. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals (Basel) 2021;14:43. [PMID: 33429973 DOI: 10.3390/ph14010043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
158 Lacin S, Yalcin S, Karakas Y, Hassan MM, Amin H, Mohamed YI, Rashid A, Morris JS, Xiao L, Qayyum A, Kaseb AO. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. J Hepatocell Carcinoma 2020;7:143-53. [PMID: 32984091 DOI: 10.2147/JHC.S258930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, Giannini EG, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F, Marra F. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer 2021;10:126-36. [PMID: 33977089 DOI: 10.1159/000513404] [Reference Citation Analysis]
160 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel) 2021;13:5018. [PMID: 34638502 DOI: 10.3390/cancers13195018] [Reference Citation Analysis]
161 Wei CY, Chen PC, Chau GY, Lee RC, Chen PH, Huo TI, Huang YH, Su YH, Hou MC, Wu JC, Su CW. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med 2020;8:238. [PMID: 32309385 DOI: 10.21037/atm.2019.12.157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
162 Hsu HY, Yu MC, Lee CW, Tsai HI, Sung CM, Chen CW, Huang SW, Lin CY, Jeng WJ, Lee WC, Chen MF. RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma. BMC Cancer. 2017;17:742. [PMID: 29121890 DOI: 10.1186/s12885-017-3748-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
163 Ho SY, Liu PH, Hsu CY, Hsia CY, Huang YH, Su CW, Lei HJ, Lee RC, Hou MC, Huo TI. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. Dig Dis Sci. 2020;65:658-667. [PMID: 31659612 DOI: 10.1007/s10620-019-05813-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
164 Tong J, Liu P, Ji M, Wang Y, Xue Q, Yang JJ, Zhou CM. Machine Learning Can Predict Total Death After Radiofrequency Ablation in Liver Cancer Patients. Clin Med Insights Oncol 2021;15:11795549211000017. [PMID: 33854400 DOI: 10.1177/11795549211000017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Roberts HJ, Wo JY. Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. Cancer 2021. [PMID: 34847255 DOI: 10.1002/cncr.34033] [Reference Citation Analysis]
166 Cho Y, Kim JW, Kim JK, Lee KS, Lee JI, Lee HW, Lee KH, Joo SM, Lim JH, Lee IJ. Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1612. [PMID: 32570869 DOI: 10.3390/cancers12061612] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
167 Lin CW, Chen YS, Lin CC, Lee PH, Lo GH, Hsu CC, Hsieh PM, Koh KW, Bair MJ, Dai CY, Huang JF, Chuang WL, Chen YL, Yu ML. Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. PLoS One 2018;13:e0202650. [PMID: 30180193 DOI: 10.1371/journal.pone.0202650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
168 Campani C, Bensi C, Milani S, Galli A, Tarocchi M. Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. J Hepatocell Carcinoma 2020;7:107-16. [PMID: 32802809 DOI: 10.2147/JHC.S252506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
169 Villanueva A. Selected summary for the 2015 Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE). Hepat Oncol 2016;3:5-8. [PMID: 30191022 DOI: 10.2217/hep.15.37] [Reference Citation Analysis]
170 Zhao Z, Zhu Y, Ni X, Lin J, Li H, Zheng L, Zhang C, Qi X, Huo H, Lou X, Fan Q, Bao Y, Luo M. Serum GGT/ALT ratio predicts vascular invasion in HBV-related HCC. Cancer Cell Int 2021;21:517. [PMID: 34583704 DOI: 10.1186/s12935-021-02214-1] [Reference Citation Analysis]
171 Miwa T, Kanda M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y. Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy. J Gastric Cancer 2019;19:183-92. [PMID: 31245163 DOI: 10.5230/jgc.2019.19.e15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
172 Xu W, Li R, Liu F. Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Cancer Manag Res. 2020;12:1693-1712. [PMID: 32214844 DOI: 10.2147/cmar.s241959] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
173 Chan SL, Wong LL, Chan KA, Chow C, Tong JH, Yip TC, Wong GL, Chong CC, Liu PH, Chu CM, Wong VW, To KF, Reeves HL, Chan AW. Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. Liver Cancer 2020;9:167-81. [PMID: 32399431 DOI: 10.1159/000504252] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
174 Antkowiak M, Gabr A, Das A, Ali R, Kulik L, Ganger D, Moore C, Abecassis M, Katariya N, Mouli S, Mahalingam D, Lewandowski RJ, Salem R, Riaz A. Prognostic Role of Albumin, Bilirubin, and ALBI Scores: Analysis of 1000 Patients with Hepatocellular Carcinoma Undergoing Radioembolization. Cancers (Basel). 2019;11. [PMID: 31238514 DOI: 10.3390/cancers11060879] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
175 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, He YJ, Lee YH, Huang YH, Hou MC, Huo TI. Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Sci Rep 2018;8:15074. [PMID: 30305679 DOI: 10.1038/s41598-018-33536-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
176 Li Y, Han B, Li H, Song T, Bao W, Wang R, Bai Z, Zheng K, Li Q, Guo X, Qi X. Effect of Admission Time on the Outcomes of Liver Cirrhosis with Acute Upper Gastrointestinal Bleeding: Regular Hours versus Off-Hours Admission. Can J Gastroenterol Hepatol 2018;2018:3541365. [PMID: 30631756 DOI: 10.1155/2018/3541365] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
177 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 18.0] [Reference Citation Analysis]
178 Li W, Xu L, Han J, Yuan K, Wu H. Identification and Validation of Tumor Stromal Immunotype in Patients With Hepatocellular Carcinoma. Front Oncol 2019;9:664. [PMID: 31448222 DOI: 10.3389/fonc.2019.00664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
179 Zhao M, Zhang M, Wang Y, Yang X, Teng X, Chu G, Wang X, Niu H. Prognostic Value of Preoperative Albumin-to-Alkaline Phosphatase Ratio in Patients with Muscle-Invasive Bladder Cancer After Radical Cystectomy. Onco Targets Ther 2020;13:13265-74. [PMID: 33402835 DOI: 10.2147/OTT.S285098] [Reference Citation Analysis]
180 Hiraoka A, Kato M, Marui K, Murakami T, Onishi K, Adachi T, Matsuoka J, Ueki H, Yoshino T, Tsuruta M, Aibiki T, Okudaira T, Kuroda T, Iwasaki R, Suga Y, Miyata H, Ninomiya T, Hirooka M, Abe M, Matsuura B, Michitaka K, Hiasa Y. Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker. Cancer Med 2021;10:3584-92. [PMID: 33960691 DOI: 10.1002/cam4.3908] [Reference Citation Analysis]
181 Franck M, Schütte K, Malfertheiner P, Link A. Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors. World J Gastroenterol 2020; 26(1): 86-96 [PMID: 31933516 DOI: 10.3748/wjg.v26.i1.86] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
182 Cho WR, Hung CH, Chen CH, Lin CC, Wang CC, Liu YW, Wu YJ, Yong CC, Chen KD, Tsai YC, Hu TH, Tsai MC. Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery. Sci Rep 2020;10:7290. [PMID: 32350365 DOI: 10.1038/s41598-020-64354-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
183 Duan J, Wu Y, Liu J, Zhang J, Fu Z, Feng T, Liu M, Han J, Li Z, Chen S. Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.J Hepatocell Carcinoma. 2019;6:151-166. [PMID: 31696097 DOI: 10.2147/JHC.S224849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
184 Wu HL, Kuo HC, Li CC, Wu YM, Lin SP, Chang KY, Hou MC, Tsou MY, Cherng YG, Chen JT, Tai YH. A comparison of prognostic performance of perioperative inflammation markers in surgical resection for hepatocellular carcinoma. J Chin Med Assoc 2021;84:614-22. [PMID: 33883464 DOI: 10.1097/JCMA.0000000000000534] [Reference Citation Analysis]
185 Tsai YC, Sou FM, Liu YW, Wu YJ, Yong CC, Chen DW, Huang PY, Cho WR, Chuang CH, Hsiao CC, Hu TH, Tsai MC. Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. BMC Gastroenterol 2021;21:386. [PMID: 34666694 DOI: 10.1186/s12876-021-01944-w] [Reference Citation Analysis]
186 He H, Ji B, Jia Z, Zhang Y, Wang X, Tao X, Liu Y, Jiang J. A Practical Model is Equivalent to the BALAD or BALAD-2 Score in Predicting Long-term Survival after Hepatectomy in Chinese Patients with Hepatocellular Carcinoma. J Cancer 2021;12:1474-82. [PMID: 33531992 DOI: 10.7150/jca.51593] [Reference Citation Analysis]
187 Ozaki K, Ishida T, Ohtani T, Shimada M, Kimura H, Gabata T. Assessing the progression of segmental fibrosis in chronic liver disease using extracellular volume fractions. Eur J Radiol 2021;145:110033. [PMID: 34808581 DOI: 10.1016/j.ejrad.2021.110033] [Reference Citation Analysis]
188 Ueno M, Komeda K, Kosaka H, Nakai T, Nomi T, Iida H, Tanaka S, Ikoma H, Matsuda K, Hirokawa F, Matsumoto M, Hokuto D, Mori H, Morimura R, Kaibori M, Yamaue H, Kubo S. Prognostic impact of neoadjuvant chemotherapy in patients with synchronous colorectal liver metastasis: A propensity score matching comparative study. Int J Surg 2021;94:106106. [PMID: 34536602 DOI: 10.1016/j.ijsu.2021.106106] [Reference Citation Analysis]
189 Hiraoka A, Tanizawa Y, Huang YJ, Cai Z, Sakaguchi S. Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database. Drugs Real World Outcomes 2021;8:301-14. [PMID: 33792850 DOI: 10.1007/s40801-021-00245-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
190 El Naqa I, Johansson A, Owen D, Cuneo K, Cao Y, Matuszak M, Bazzi L, Lawrence TS, Ten Haken RK. Modeling of Normal Tissue Complications Using Imaging and Biomarkers After Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2018;100:335-43. [PMID: 29353652 DOI: 10.1016/j.ijrobp.2017.10.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
191 Abe T, Tashiro H, Kobayashi T, Hattori M, Kuroda S, Ohdan H. Glasgow Prognostic Score and Prognosis After Hepatectomy for Hepatocellular Carcinoma. World J Surg 2017;41:1860-70. [PMID: 28197709 DOI: 10.1007/s00268-017-3909-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
192 Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers (Basel) 2019;11:E1517. [PMID: 31601010 DOI: 10.3390/cancers11101517] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
193 Tomita K, Chiba N, Ochiai S, Gunji T, Hikita K, Kobayashi T, Sano T, Abe Y, Koizumi K, Shimazu M, Kawachi S. Prognostic value of future liver remnant LU15 index of 99mTc-galactosyl serum albumin scintigraphy for predicting posthepatectomy liver failure. PLoS One 2021;16:e0247675. [PMID: 33621268 DOI: 10.1371/journal.pone.0247675] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Akarapatima K, Chang A, Prateepchaiboon T, Pungpipattrakul N, Songjamrat A, Pakdeejit S, Rattanasupar A, Piratvisuth T. Predictive Outcomes Using Child-Turcotte-Pugh and Albumin-Bilirubin Scores in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. J Gastrointest Cancer 2021. [PMID: 34761340 DOI: 10.1007/s12029-021-00743-6] [Reference Citation Analysis]
195 Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology 2020;72:198-212. [PMID: 31698504 DOI: 10.1002/hep.31022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
196 Toesca DAS, Ibragimov B, Koong AJ, Xing L, Koong AC, Chang DT. Strategies for prediction and mitigation of radiation-induced liver toxicity. J Radiat Res 2018;59:i40-9. [PMID: 29432550 DOI: 10.1093/jrr/rrx104] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
197 Simeth J, Johansson A, Owen D, Cuneo K, Mierzwa M, Feng M, Lawrence TS, Cao Y. Quantification of liver function by linearization of a two-compartment model of gadoxetic acid uptake using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2018;31:e3913. [PMID: 29675932 DOI: 10.1002/nbm.3913] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
198 Metra BM, Guglielmo FF, Halegoua-DeMarzio DL, Civan JM, Mitchell DG. Beyond the Liver Function Tests: A Radiologist's Guide to the Liver Blood Tests. Radiographics 2021;:210137. [PMID: 34797734 DOI: 10.1148/rg.210137] [Reference Citation Analysis]
199 Yılmaz A, Şimşek M, Hannarici Z, Büyükbayram ME, Bilici M, Tekin SB. The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib. Future Oncol 2021;17:4545-59. [PMID: 34431372 DOI: 10.2217/fon-2021-0457] [Reference Citation Analysis]
200 Yu JI, Park HC, Yoo GS, Paik SW, Choi MS, Kim HS, Sohn I, Nam H. Clinical Significance of Systemic Inflammation Markers in Newly Diagnosed, Previously Untreated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1300. [PMID: 32455607 DOI: 10.3390/cancers12051300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
201 Nishikawa H, Yoh K, Enomoto H, Iwata Y, Sakai Y, Kishino K, Shimono Y, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Koriyama T, Yuri Y, Nishimura T, Nishiguchi S, Iijima H. Close Correlation between Frailty and Depressive State in Chronic Liver Diseases. Medicina (Kaunas) 2020;56:E319. [PMID: 32605049 DOI: 10.3390/medicina56070319] [Reference Citation Analysis]
202 Hu K, Yuan J, Tang B, Zhang F, Lu S, Chen R, Zhang L, Ren Z, Yin X. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. Ann Transl Med 2021;9:237. [PMID: 33708864 DOI: 10.21037/atm-20-3118] [Reference Citation Analysis]
203 Kumada T, Toyoda H, Tada T, Yasuda S, Tanaka J. Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer 2020;9:518-28. [PMID: 33083278 DOI: 10.1159/000507933] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
204 Shibutani K, Okada M, Tsukada J, Hyodo T, Ibukuro K, Abe H, Matsumoto N, Midorikawa Y, Moriyama M, Takayama T. A proposed model on MR elastography for predicting postoperative major complications in patients with hepatocellular carcinoma. BJR Open 2021;3:20210019. [PMID: 34877453 DOI: 10.1259/bjro.20210019] [Reference Citation Analysis]
205 Ke MY, Wu XN, Zhang Y, Wang S, Lv Y, Dong J. Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma. J Transl Med 2019;17:140. [PMID: 31046807 DOI: 10.1186/s12967-019-1889-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
206 Sinn DH, Choi GS, Park HC, Kim JM, Kim H, Song KD, Kang TW, Lee MW, Rhim H, Hyun D, Cho SK, Shin SW, Jeong WK, Kim SH, Yu JI, Ha SY, Lee SJ, Lim HY, Kim K, Ahn JH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Joh JW, Lim HK, Paik SW. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One. 2019;14:e0210730. [PMID: 30640924 DOI: 10.1371/journal.pone.0210730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
207 Ogawa E, Kawano A, Ooho A, Furusyo N, Satoh T, Takahashi K, Kajiwara E, Dohmen K, Nakamuta M, Azuma K, Koyanagi T, Yamashita N, Yanagita K, Ichiki Y, Kuniyoshi M, Yamashita N, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection. J Gastroenterol Hepatol 2021. [PMID: 34618379 DOI: 10.1111/jgh.15703] [Reference Citation Analysis]
208 Umino R, Kobayashi Y, Akabane M, Kojima K, Okubo S, Hashimoto M, Shindoh J. Preoperative nutritional score predicts underlying liver status and surgical risk of hepatocellular carcinoma. Scand J Surg 2021;:14574969211061953. [PMID: 34931568 DOI: 10.1177/14574969211061953] [Reference Citation Analysis]
209 Guarino M, Caporaso N, Morisco F. Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy. Ann Transl Med 2020;8:1282. [PMID: 33209862 DOI: 10.21037/atm-20-6004] [Reference Citation Analysis]
210 Koay EJ, Owen D, Das P. Radiation-Induced Liver Disease and Modern Radiotherapy. Semin Radiat Oncol 2018;28:321-31. [PMID: 30309642 DOI: 10.1016/j.semradonc.2018.06.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
211 Yuan G, Song Y, Li Q, Hu X, Zang M, Dai W, Cheng X, Huang W, Yu W, Chen M, Guo Y, Zhang Q, Chen J. Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. Front Immunol 2020;11:613946. [PMID: 33488622 DOI: 10.3389/fimmu.2020.613946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Yoneoka G, Bozhilov K, Wong LL. Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma. Hepatoma Res 2020;6:67. [PMID: 33134551 DOI: 10.20517/2394-5079.2020.57] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
213 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
214 Sonohara F, Yamada S, Tanaka N, Suenaga M, Takami H, Hayashi M, Niwa Y, Sugimoto H, Hattori N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y. Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma. Ann Gastroenterol Surg. 2019;3:65-74. [PMID: 30697612 DOI: 10.1002/ags3.12212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
215 Su TS, Yang HM, Zhou Y, Huang Y, Liang P, Cheng T, Chen L, Li LQ, Liang SX. Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy. Radiat Oncol. 2019;14:50. [PMID: 30917853 DOI: 10.1186/s13014-019-1251-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
216 Bannaga A, Arasaradnam RP. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. World J Gastroenterol 2020; 26(33): 5022-5049 [PMID: 32952347 DOI: 10.3748/wjg.v26.i33.5022] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Fang KC, Kao WY, Su CW, Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer. 2018;7:335-358. [PMID: 30488023 DOI: 10.1159/000487407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
218 Zeng J, Lin K, Liu H, Huang Y, Guo P, Zeng Y, Zeng J, Liu J. Prognosis Factors of Young Patients Undergoing Curative Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma: A Multicenter Study. Cancer Manag Res 2020;12:6597-606. [PMID: 32848453 DOI: 10.2147/CMAR.S261368] [Reference Citation Analysis]
219 Azar A, Devcic Z, Paz-Fumagalli R, Vidal LLC, McKinney JM, Frey G, Lewis AR, Ritchie C, Starr JS, Mody K, Toskich B. Albumin-bilirubin grade as a prognostic indicator for patients with non-hepatocellular primary and metastatic liver malignancy undergoing Yttrium-90 radioembolization using resin microspheres. J Gastrointest Oncol 2020;11:715-23. [PMID: 32953155 DOI: 10.21037/jgo.2020.04.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
220 Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One 2017;12:e0188552. [PMID: 29176777 DOI: 10.1371/journal.pone.0188552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
221 Gkika E, Bettinger D, Krafft L, Schultheiss M, Neeff HP, Maruschke L, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu A, Brunner TB. The role of albumin–bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlenther Onkol 2018;194:403-13. [DOI: 10.1007/s00066-017-1256-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
222 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers (Basel) 2021;13:3961. [PMID: 34439116 DOI: 10.3390/cancers13163961] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Wang H, Lin C, Fan W, Zhang J, Zhang Y, Yao W, Li J. Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancer Manag Res 2020;12:3433-44. [PMID: 32523374 DOI: 10.2147/CMAR.S245396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
224 Shimamura Y, Abe K, Maeda T, Matsui T, Ishiguro A, Takizawa H. Association Between Renal Adverse Effects and Mortality in Patients With Hepatocellular Carcinoma Treated With Lenvatinib. In Vivo 2021;35:1647-53. [PMID: 33910848 DOI: 10.21873/invivo.12423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
225 Lee YH, Koh YS, Hur YH, Cho CK, Kim HJ, Park EK. Effectiveness of the albumin-bilirubin score as a prognostic factor for early recurrence after curative hepatic resection for hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg 2018;22:335-43. [PMID: 30588524 DOI: 10.14701/ahbps.2018.22.4.335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
226 Campani C, Capone M, Liotta F, Arena U, Adotti V, Di Bonaventura C, Aburas S, Colagrande S, Calistri L, Annunziato F, Marra F. Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. Dig Liver Dis 2021:S1590-8658(21)00850-1. [PMID: 34876355 DOI: 10.1016/j.dld.2021.11.010] [Reference Citation Analysis]
227 Zhou Z, Qi L, Mo Q, Liu Y, Zhou X, Zhou Z, Liang X, Feng S, Yu H. Effect of surgical margin on postoperative prognosis in patients with solitary hepatocellular carcinoma: A propensity score matching analysis. J Cancer 2021;12:4455-62. [PMID: 34149909 DOI: 10.7150/jca.57896] [Reference Citation Analysis]
228 Peng Y, Wei Q, Liu Y, Wu Z, Zhang H, Wu H, Chai J. Prediction and Risk Factors for Prognosis of Cirrhotic Patients with Hepatic Encephalopathy. Gastroenterol Res Pract 2021;2021:5623601. [PMID: 34712321 DOI: 10.1155/2021/5623601] [Reference Citation Analysis]
229 Wang Q, Han G. Image-guided treatment of Budd-Chiari syndrome: a giant leap from the past, a small step towards the future. Abdom Radiol 2018;43:1908-19. [DOI: 10.1007/s00261-017-1341-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
230 Liao R, Du CY, Gong JP, Luo F. HBV-DNA Load-Related Peritumoral Inflammation and ALBI Scores Predict HBV Associated Hepatocellular Carcinoma Prognosis after Curative Resection. J Oncol 2018;2018:9289421. [PMID: 30327670 DOI: 10.1155/2018/9289421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
231 Maruta S, Ogasawara S, Ooka Y, Obu M, Inoue M, Itokawa N, Haga Y, Seki A, Okabe S, Azemoto R, Itobayashi E, Atsukawa M, Sugiura N, Mizumoto H, Koroki K, Kanayama K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer. 2020;9:382-396. [PMID: 32999866 DOI: 10.1159/000507022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
232 Sung PS, Jang JW, Lee J, Lee SK, Lee HL, Yang H, Nam HC, Lee SW, Bae SH, Choi JY, Han NI, Yoon SK. Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection. Front Oncol. 2020;10:1043. [PMID: 32695681 DOI: 10.3389/fonc.2020.01043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
233 Sun LY, Ouyang Q, Cen WJ, Wang F, Tang WT, Shao JY. A Model Based on Artificial Intelligence Algorithm for Monitoring Recurrence of HCC after Hepatectomy. Am Surg 2021;:31348211063549. [PMID: 34894786 DOI: 10.1177/00031348211063549] [Reference Citation Analysis]
234 Wu MT, He SY, Chen SL, Li LF, He ZQ, Zhu YY, He X, Chen H. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma.BMC Cancer. 2019;19:538. [PMID: 31164099 DOI: 10.1186/s12885-019-5747-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
235 Zhang Y, Huang C, Nie Y, Liu Q, Xiao N, Liu L, Zhu X. Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis. Front Med (Lausanne) 2021;8:698502. [PMID: 34336902 DOI: 10.3389/fmed.2021.698502] [Reference Citation Analysis]
236 Kawaguchi T, Shimose S, Yamamura S, Nakano D, Tanaka M, Torimura T. Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then. Ann Transl Med 2020;8:1045. [PMID: 33145264 DOI: 10.21037/atm-2020-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
237 Ishikawa K, Chiba T, Ooka Y, Suzuki E, Ogasawara S, Maeda T, Yokoyama M, Inoue M, Wakamatsu T, Kusakabe Y, Saito T, Tawada A, Arai M, Kanda T, Maruyama H, Imazeki F, Kato N. Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. Oncotarget 2018;9:21560-8. [PMID: 29765560 DOI: 10.18632/oncotarget.25108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
238 Zhang W, Liu C, Tan Y, Tan L, Jiang L, Yang J, Yang J, Yan L, Wen T. Albumin-Bilirubin Score for Predicting Post-Transplant Complications Following Adult-to-Adult Living Donor Liver Transplantation. Ann Transplant 2018;23:639-46. [PMID: 30201946 DOI: 10.12659/AOT.910824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
239 Rovesti G, Orsi G, Kalliopi A, Vivaldi C, Marisi G, Faloppi L, Foschi FG, Silvestris N, Pecora I, Aprile G, Molinaro E, Riggi L, Ulivi P, Canale M, Cucchetti A, Tamburini E, Ercolani G, Fornaro L, Andreone P, Zavattari P, Scartozzi M, Cascinu S, Casadei-Gardini A. Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointest Tumors 2019;6:92-107. [PMID: 31768353 DOI: 10.1159/000502714] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
240 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Itobayashi E, Nouso K, Kariyama K, Ishikawa T, Hirooka M, Hiasa Y. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. Cancer Sci. 2017;108:1414-1420. [PMID: 28406546 DOI: 10.1111/cas.13257] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
241 Liu J, Wu M, Xie E, Chen L, Su S, Zeng H, Geng Q, Yang F, Luo J. Assessment of Liver Function for Evaluation of Short- and Long-Term Outcomes in Type B Aortic Dissection Patients Undergoing Thoracic Endovascular Aortic Repair. Front Cardiovasc Med 2021;8:643127. [PMID: 34124186 DOI: 10.3389/fcvm.2021.643127] [Reference Citation Analysis]
242 Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L, Abdulrahman A, Kudo M, Thimme R, Park JW, Pinato DJ. Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. Liver Cancer 2017;6:313-24. [PMID: 29234635 DOI: 10.1159/000480441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
243 Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M;  Liver Cancer Study Group of Japan. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol. 2017;52:1112-1121. [PMID: 28224228 DOI: 10.1007/s00535-017-1321-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
244 Chu MO, Shen CH, Chang TS, Xu HW, Yen CW, Lu SN, Hung CH. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. Sci Rep 2018;8:16611. [PMID: 30413724 DOI: 10.1038/s41598-018-34543-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
245 Kusakabe J, Firl DJ, Sasaki K. Toward the universal scoring system in treatment for patients with hepatocellular carcinoma. J Hepatol 2019;70:568-70. [PMID: 30554931 DOI: 10.1016/j.jhep.2018.10.024] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
246 Liu W, Yang Z, Zou R, Qiu J, Shen J, Liao Y, Wang C, Zhang Y, Wang Y, Yuan Y, Li K, Zuo D, He W, Zheng Y, Li B, Yuan Y. Resection vs Ablation for Multifocal Hepatocellular Carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: A Propensity Score Matching Study. J Cancer 2019;10:2857-67. [PMID: 31281462 DOI: 10.7150/jca.31246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
247 Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Aoki T, Tanaka T, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Arai T, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep 2021;11:16663. [PMID: 34404856 DOI: 10.1038/s41598-021-96089-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
248 Onali S, Figorilli F, O'Beirne J. Selection criteria for resection in hepatocellular carcinoma: Can we expand them? Hepatology 2016;64:313. [PMID: 26317503 DOI: 10.1002/hep.28141] [Reference Citation Analysis]
249 Ma T, Li QS, Wang Y, Wang B, Wu Z, Lv Y, Wu RQ. Value of pretransplant albumin-bilirubin score in predicting outcomes after liver transplantation. World J Gastroenterol 2019; 25(15): 1879-1889 [PMID: 31057301 DOI: 10.3748/wjg.v25.i15.1879] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
250 Shao L, Han B, An S, Ma J, Guo X, Romeiro FG, Mancuso A, Qi X. Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis. Transl Gastroenterol Hepatol 2017;2:88. [PMID: 29264426 DOI: 10.21037/tgh.2017.09.11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
251 Fujita K, Nomura T, Morishita A, Shi T, Oura K, Tani J, Kobara H, Tsutsui K, Himoto T, Masaki T. Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis. J Clin Med 2019;8:E1258. [PMID: 31430975 DOI: 10.3390/jcm8081258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
252 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
253 Hsieh YC, Lee KC, Wang YW, Yang YY, Hou MC, Huo TI, Lin HC. Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score. PLoS One 2018;13:e0208903. [PMID: 30540824 DOI: 10.1371/journal.pone.0208903] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
254 Yu SCH, Hui JW, Li L, Cho CC, Hui EP, Chan SL, Yeo WM. Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥ 10 cm) in Tumour Response and Long-Term Survival Outcome. Cardiovasc Intervent Radiol 2021. [PMID: 34604920 DOI: 10.1007/s00270-021-02777-6] [Reference Citation Analysis]
255 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
256 Naqvi IH, Talib A, Mahmood K, Abidi R, Rizvi SNZ. The ability of the new ALBI scoring in predicting mortality, complications and prognostic comparison among cirrhotics. Prz Gastroenterol 2019;14:250-7. [PMID: 31988671 DOI: 10.5114/pg.2019.83872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
257 Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Sugimoto K, Hasegawa H, Takei Y. Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma. PLoS One 2020;15:e0237370. [PMID: 32857769 DOI: 10.1371/journal.pone.0237370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
258 Liu QP, Xu X, Zhu FP, Zhang YD, Liu XS. Prediction of prognostic risk factors in hepatocellular carcinoma with transarterial chemoembolization using multi-modal multi-task deep learning.EClinicalMedicine. 2020;23:100379. [PMID: 32548574 DOI: 10.1016/j.eclinm.2020.100379] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
259 Abe K, Wakabayashi H, Nakayama H, Suzuki T, Kuroda M, Yoshida N, Tojo J, Kogure A, Rai T, Saito H, Mukai S, Fujita M, Hayashi M, Takahashi A, Ohira H. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis. PLoS One 2020;15:e0243473. [PMID: 33284844 DOI: 10.1371/journal.pone.0243473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
260 Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA. LI.CA study group. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Med. 2016;13:e1002006. [PMID: 27116206 DOI: 10.1371/journal.pmed.1002006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 10.7] [Reference Citation Analysis]
261 Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer 2019;19:795. [PMID: 31409405 DOI: 10.1186/s12885-019-5989-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
262 Liu F, Liu D, Wang K, Xie X, Su L, Kuang M, Huang G, Peng B, Wang Y, Lin M, Tian J. Deep Learning Radiomics Based on Contrast-Enhanced Ultrasound Might Optimize Curative Treatments for Very-Early or Early-Stage Hepatocellular Carcinoma Patients. Liver Cancer. 2020;9:397-413. [PMID: 32999867 DOI: 10.1159/000505694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
263 Abdel-Rahman O. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. J Cancer Res Clin Oncol 2018;144:901-8. [PMID: 29455421 DOI: 10.1007/s00432-018-2610-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
264 Chen KL, Gao J. Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization. World J Gastroenterol 2021; 27(13): 1330-1340 [PMID: 33833486 DOI: 10.3748/wjg.v27.i13.1330] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Cheng R, Tan N, Kang Q, Luo H, Chen H, Pan J, Han Y, Yang Y, Xu X. High-density lipoprotein cholesterol is a predictor of survival in cirrhotic patients with acute gastrointestinal bleeding: a retrospective study. BMC Gastroenterol 2020;20:381. [PMID: 33198637 DOI: 10.1186/s12876-020-01522-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
266 Bartnik K, Hołówko W, Rowiński O. Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study. Life (Basel) 2021;11:1062. [PMID: 34685433 DOI: 10.3390/life11101062] [Reference Citation Analysis]
267 Yu SCH, Hui JWY, Chong CCN, Cho CCM, Cheung S, Wong J, Lee KF. Comparison of Survival Outcomes in Transarterial Ethanol Ablation and Liver Resection for Solitary Hepatocellular Carcinoma ≤ 5 cm in Patients Stratified by Liver Function. Cardiovasc Intervent Radiol 2021. [PMID: 34609579 DOI: 10.1007/s00270-021-02768-7] [Reference Citation Analysis]
268 Komiyama S, Numata K, Moriya S, Fukuda H, Chuma M, Maeda S. Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports. World J Clin Cases 2020; 8(12): 2574-2584 [PMID: 32607334 DOI: 10.12998/wjcc.v8.i12.2574] [Reference Citation Analysis]
269 Mizuno K, Toyoda H, Yasuda S, Tada T, Kumada T, Sone Y, Tanaka J. The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. J Gastroenterol 2019;54:829-36. [PMID: 31161311 DOI: 10.1007/s00535-019-01595-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
270 Lu LH, Wei-Wei, Kan A, Jie-Mei, Ling YH, Li SH, Guo RP. Novel Value of Preoperative Gamma-Glutamyltransferase Levels in the Prognosis of AFP-Negative Hepatocellular Carcinoma. Dis Markers 2020;2020:4269460. [PMID: 32695241 DOI: 10.1155/2020/4269460] [Reference Citation Analysis]
271 Guo G, Lei Z, Tang X, Ma W, Si A, Yang P, Li Q, Geng Z, Zhou J, Cheng Z. External Validation of Six Liver Functional Reserve Models to predict Posthepatectomy Liver Failure after Major Resection for Hepatocellular Carcinoma. J Cancer 2021;12:5260-7. [PMID: 34335942 DOI: 10.7150/jca.58726] [Reference Citation Analysis]
272 Peng C, Teng W, Hsieh Y, Jeng W, Huang C, Lui K, Hung C, Chen Y, Lin C, Lin C, Lin S, Sheen I. Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. Adv in Digestive Med 2020;7:83-92. [DOI: 10.1002/aid2.13182] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
273 Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Hepatol Commun 2020;4:1218-28. [PMID: 32766480 DOI: 10.1002/hep4.1535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
274 Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Reference Citation Analysis]
275 Nishikawa H, Yoh K, Enomoto H, Iwata Y, Sakai Y, Kishino K, Shimono Y, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Koriyama T, Yuri Y, Nishimura T, Nishiguchi S, Iijima H. Sarcopenia and Frailty in Chronic Liver Damage: Common and Different Points. In Vivo 2020;34:2549-59. [PMID: 32871784 DOI: 10.21873/invivo.12072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
276 Nishikawa H, Yoh K, Enomoto H, Iwata Y, Nishimura T, Nishiguchi S, Iijima H. Frailty and Sleep Disorder in Chronic Liver Diseases. Life (Basel) 2020;10:E137. [PMID: 32764402 DOI: 10.3390/life10080137] [Reference Citation Analysis]
277 Lu LH, Wei W, Li SH, Zhang YF, Guo RP. The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE. Aging (Albany NY) 2021;13:5358-68. [PMID: 33589570 DOI: 10.18632/aging.202468] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
278 Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Kawasaki H, Hiasa Y, Michitaka K; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer. 2017;6:204-215. [PMID: 28626732 DOI: 10.1159/000452846] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 12.4] [Reference Citation Analysis]
279 Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020;9:245-60. [PMID: 32647629 DOI: 10.1159/000507370] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
280 Suzuki T, Eguchi A, Shigefuku R, Nagao S, Morikawa M, Sugimoto K, Iwasa M, Takei Y. Accuracy of carbohydrate-deficient transferrin as a biomarker of chronic alcohol abuse during treatment for alcoholism. Hepatol Res 2022;52:120-7. [PMID: 33797850 DOI: 10.1111/hepr.13642] [Reference Citation Analysis]
281 Elshaarawy O, Alkhatib A, Elhelbawy M, Gomaa A, Allam N, Alsebaey A, Rewisha E, Waked I. Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. World J Hepatol 2019; 11(6): 542-552 [PMID: 31293722 DOI: 10.4254/wjh.v11.i6.542] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
282 Alsebaey A, Sabry A, Rashed HS, Elsabaawy MM, Ragab A, Aly RA, Badran H. MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation. Asian Pac J Cancer Prev 2021;22:2005-9. [PMID: 34319020 DOI: 10.31557/APJCP.2021.22.7.2005] [Reference Citation Analysis]
283 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
284 Ono A, Aikata H, Yamauchi M, Kodama K, Ohishi W, Kishi T, Ohya K, Teraoka Y, Osawa M, Fujino H, Nakahara T, Murakami E, Miki D, Kawaoka T, Abe-Chayama H, Zhang P, Liu S, Makokha GN, Tsuge M, Imamura M, Hayes CN, Chayama K. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. Ther Adv Med Oncol 2020;12:1758835920922051. [PMID: 32547646 DOI: 10.1177/1758835920922051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
285 Li W, Han J, Yuan K, Wu H. Integrated tumor stromal features of hepatocellular carcinoma reveals two distinct subtypes with prognostic/predictive significance. Aging (Albany NY) 2019;11:4478-509. [PMID: 31299011 DOI: 10.18632/aging.102064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
286 Yamamoto Y. Evaluation of Liver Function and the Role of Biliary Drainage before Major Hepatic Resections. Visc Med 2021;37:10-7. [PMID: 33718480 DOI: 10.1159/000512439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
287 Kokudo T, Hasegawa K, Shirata C, Tanimoto M, Ishizawa T, Kaneko J, Akamatsu N, Arita J, Demartines N, Uldry E, Kokudo N, Halkic N. Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma. Liver Cancer 2019;8:447-56. [PMID: 31799202 DOI: 10.1159/000501368] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
288 Ho SY, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, Huang YH, Lee FY, Hou MC, Tsai YJ, Huo TI. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One. 2017;12:e0180408. [PMID: 28672011 DOI: 10.1371/journal.pone.0180408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
289 Liu PH, Huo TI. Ablation for Hepatocellular Carcinoma: Where Do We Stand? Ann Surg 2017;266:e55-6. [PMID: 29136965 DOI: 10.1097/SLA.0000000000001380] [Reference Citation Analysis]
290 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26:516-28. [PMID: 32911589 DOI: 10.3350/cmh.2020.0016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
291 Wang Q, Su B, Dong L, Jiang T, Tan Y, Lu X, Liu X, Lin X, Xu G. Liquid Chromatography-Mass Spectrometry-Based Nontargeted Metabolomics Predicts Prognosis of Hepatocellular Carcinoma after Curative Resection. J Proteome Res. 2020;19:3533-3541. [PMID: 32618195 DOI: 10.1021/acs.jproteome.0c00344] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
292 Hiraoka A, Kumada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Yokohama K, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M. Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer 2020;9:73-83. [PMID: 32071911 DOI: 10.1159/000503031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
293 Lei Q, Zhang Y, Ke C, Yan C, Huang P, Shen H, Lei H, Chen Y, Luo J, Meng Z. Value of the albumin-bilirubin score in the evaluation of hepatitis B virus-related acute-on-chronic liver failure, liver cirrhosis, and hepatocellular carcinoma. Exp Ther Med. 2018;15:3074-3079. [PMID: 29456711 DOI: 10.3892/etm.2018.5748] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
294 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Combined Albumin-Bilirubin Grade and Skeletal Muscle Mass as a Predictor in Liver Cirrhosis. J Clin Med 2019;8:E782. [PMID: 31159435 DOI: 10.3390/jcm8060782] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
295 Oh JH, Sinn DH, Choi GS, Kim JM, Joh JW, Kang TW, Hyun D, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res 2020;99:238-46. [PMID: 33029483 DOI: 10.4174/astr.2020.99.4.238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
296 Kumada T, Toyoda H, Yasuda S, Ito T, Tanaka J. Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population. Hepatol Res 2022;52:81-92. [PMID: 34665918 DOI: 10.1111/hepr.13723] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
297 Burkhart RA, Pawlik TM. Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control 2017;24:1073274817729235. [PMID: 28975828 DOI: 10.1177/1073274817729235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
298 Wei L, Delin Z, Kefei Y, Hong W, Jiwei H, Yange Z. A classification based on tumor budding and immune score for patients with hepatocellular carcinoma. Oncoimmunology 2020;9:1672495. [PMID: 32002283 DOI: 10.1080/2162402X.2019.1672495] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
299 Torimura T, Iwamoto H. Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. Clin Mol Hepatol 2021;27:236-45. [PMID: 33317248 DOI: 10.3350/cmh.2020.0204] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
300 Wang L, Jin YX, Ji YZ, Mu Y, Zhang SC, Pan SY. Development and validation of a prediction model for microvascular invasion in hepatocellular carcinoma. World J Gastroenterol 2020; 26(14): 1647-1659 [PMID: 32327913 DOI: 10.3748/wjg.v26.i14.1647] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
301 Wallace MC, Knuiman M, Huang Y, Garas G, Adams LA, MacQuillan G, Preen DB, Jeffrey GP. The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable. Dig Dis Sci 2018;63:2277-84. [PMID: 29808245 DOI: 10.1007/s10620-018-5132-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
302 Long H, Zhong X, Su L, Huang T, Duan Y, Ke W, Xie X, Lin M. Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2021. [PMID: 34379248 DOI: 10.1245/s10434-021-10563-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
303 Zhao S, Zhang T, Li H, Wang M, Xu K, Zheng D, Du X, Liu L. Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC. Ann Transl Med 2020;8:538. [PMID: 32411761 DOI: 10.21037/atm.2020.02.124] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
304 Takatsu Y, Nakamura M, Kobayashi S, Miyati T. Prediction of Sufficient Liver Enhancement on the Gadoxetate Disodium-enhanced Hepatobiliary Phase Imaging Using Transitional Phase Images and Albumin-bilirubin Grade. Magn Reson Med Sci 2021;20:152-9. [PMID: 32461506 DOI: 10.2463/mrms.mp.2020-0050] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
305 Braat MNGJA, de Jong HW, Seinstra BA, Scholten MV, van den Bosch MAAJ, Lam MGEH. Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients. EJNMMI Res 2017;7:2. [PMID: 28058660 DOI: 10.1186/s13550-016-0248-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
306 van der Velden S, Braat MNGJA, Labeur TA, Scholten MV, van Delden OM, Bennink RJ, de Jong HWAM, Lam MGEH. A Pilot Study on Hepatobiliary Scintigraphy to Monitor Regional Liver Function in 90Y Radioembolization. J Nucl Med 2019;60:1430-6. [PMID: 30954942 DOI: 10.2967/jnumed.118.224394] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
307 Frager SZ, Schwartz JM. Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. Curr Oncol 2020;27:S138-43. [PMID: 33343207 DOI: 10.3747/co.27.7181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
308 Xu Q, Yan Y, Gu S, Mao K, Zhang J, Huang P, Zhou Z, Chen Z, Zheng S, Liang J, Lin Z, Wang J, Yan J, Xiao Z. A Novel Inflammation-Based Prognostic Score: The Fibrinogen/Albumin Ratio Predicts Prognoses of Patients after Curative Resection for Hepatocellular Carcinoma. J Immunol Res. 2018;2018:4925498. [PMID: 30027102 DOI: 10.1155/2018/4925498] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
309 Osu N, Shiba S, Shibuya K, Okazaki S, Miyasaka Y, Okamoto M, Ohno T. Carbon-ion radiotherapy subsequent to balloon-occluded retrograde transvenous obliteration for hepatocellular carcinoma with hepatic encephalopathy: a multidisciplinary approach. Clin J Gastroenterol 2021;14:852-7. [PMID: 33811604 DOI: 10.1007/s12328-021-01395-6] [Reference Citation Analysis]
310 Toyoda H, Kumada T, Tada T, Yama T, Mizuno K, Sone Y, Maeda A, Kaneoka Y, Akita T, Tanaka J. Differences in the impact of prognostic factors for hepatocellular carcinoma over time. Cancer Sci 2017;108:2438-44. [PMID: 28945309 DOI: 10.1111/cas.13406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
311 Wu MY, Qiao Q, Wang K, Ji GW, Cai B, Li XC. Development and Validation of Pre- and Post-Operative Models to Predict Recurrence After Resection of Solitary Hepatocellular Carcinoma: A Multi-Institutional Study. Cancer Manag Res 2020;12:3503-12. [PMID: 32523380 DOI: 10.2147/CMAR.S251413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
312 Moctezuma-Velazquez C, Montano-Loza AJ, Meza-Junco J, Burak K, Ma M, Bain VG, Kneteman N, Sarlieve P, Owen RJ. Selective Internal Radiation Therapy for Hepatocellular Carcinoma Across the Barcelona Clinic Liver Cancer Stages. Dig Dis Sci 2021;66:899-911. [PMID: 32281043 DOI: 10.1007/s10620-020-06245-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Lin ZX, Ruan DY, Jia CC, Wang TT, Cheng JT, Huang HQ, Wu XY. Controlling nutritional status (CONUT) score-based nomogram to predict overall survival of patients with HBV-associated hepatocellular carcinoma after curative hepatectomy. Clin Transl Oncol 2020;22:370-80. [PMID: 31201606 DOI: 10.1007/s12094-019-02137-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
314 Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. [PMID: 34518290 DOI: 10.1136/jitc-2021-002794] [Reference Citation Analysis]
315 Zhang CH, Ni XC, Chen BY, Qiu SJ, Zhu YM, Luo M. Combined preoperative albumin-bilirubin (ALBI) and serum γ-glutamyl transpeptidase (GGT) predicts the outcome of hepatocellular carcinoma patients following hepatic resection.J Cancer. 2019;10:4836-4845. [PMID: 31598154 DOI: 10.7150/jca.33877] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
316 Yu JI, Choi C, Ha SY, Park CK, Kang SY, Joh JW, Paik SW, Kim S, Kim M, Jung SH, Park HC. Clinical importance of TERT overexpression in hepatocellular carcinoma treated with curative surgical resection in HBV endemic area. Sci Rep 2017;7:12258. [PMID: 28947783 DOI: 10.1038/s41598-017-12469-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
317 Saeki I, Yamasaki T, Maeda M, Kawano R, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. Liver Cancer 2018;7:359-71. [PMID: 30488024 DOI: 10.1159/000487858] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
318 Takada K, Takamori S, Shimokawa M, Toyokawa G, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy. ESMO Open 2021;7:100348. [PMID: 34942439 DOI: 10.1016/j.esmoop.2021.100348] [Reference Citation Analysis]
319 Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control 2018;25:1073274817744621. [PMID: 29327594 DOI: 10.1177/1073274817744621] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
320 Sakamoto Y, Yoshio S, Doi H, Mori T, Matsuda M, Kawai H, Shimagaki T, Yoshikawa S, Aoki Y, Osawa Y, Yoshida Y, Arai T, Itokawa N, Atsukawa M, Ito T, Honda T, Mise Y, Ono Y, Takahashi Y, Saiura A, Taketomi A, Kanto T. Increased Frequency of Dysfunctional Siglec-7-CD57+PD-1+ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. Front Immunol 2021;12:603133. [PMID: 33692781 DOI: 10.3389/fimmu.2021.603133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
321 Jing CY, Fu YP, Yi Y, Zhang MX, Zheng SS, Huang JL, Gan W, Xu X, Lin JJ, Zhang J, Qiu SJ, Zhang BH. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. J Immunother Cancer 2019;7:77. [PMID: 30885276 DOI: 10.1186/s40425-019-0554-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
322 Qi X, Li J, Deng H, Li H, Su C, Guo X. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Oncotarget. 2016;7:45283-45301. [PMID: 27304193 DOI: 10.18632/oncotarget.9942] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 13.3] [Reference Citation Analysis]
323 Li J, Liao Y, Suo L, Zhu P, Chen X, Dang W, Liao M, Qin L, Liao W. A novel prognostic index-neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio (NγLR) predicts outcome for patients with hepatocellular carcinoma. Sci Rep 2017;7:9229. [PMID: 28835713 DOI: 10.1038/s41598-017-09696-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
324 Yeh JH, Hung CH, Wang JH, Chen CH, Kee KM, Kuo CM, Yen YH, Cheng YF, Chen YY, Hsu HC, Lu SN. Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. PLoS One 2015;10:e0144893. [PMID: 26661388 DOI: 10.1371/journal.pone.0144893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
325 Yamamoto S, Midorikawa Y, Nagae G, Tatsuno K, Ueda H, Moriyama M, Takayama T, Aburatani H. Spatial and temporal expansion of intrahepatic metastasis by molecularly-defined clonality in multiple liver cancers.Cancer Sci. 2020;111:601-609. [PMID: 31845427 DOI: 10.1111/cas.14282] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
326 Ohkoshi-Yamada M, Kamimura K, Shibata O, Morita S, Kaidu M, Nakano T, Maruyama K, Ota A, Saito H, Yamana N, Oshikane T, Goto Y, Yoshimura N, Tanabe S, Nakano H, Sakai M, Tanaka Y, Koseki Y, Arao Y, Abe H, Setsu T, Sakamaki A, Yokoo T, Kamimura H, Aoyama H, Terai S. Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and its Role in Multidisciplinary Therapy. Cancers (Basel) 2020;12:E2955. [PMID: 33066141 DOI: 10.3390/cancers12102955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
327 Matsukane R, Watanabe H, Hata K, Suetsugu K, Tsuji T, Egashira N, Nakanishi Y, Okamoto I, Ieiri I. Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. Sci Rep 2021;11:15057. [PMID: 34301991 DOI: 10.1038/s41598-021-94336-9] [Reference Citation Analysis]
328 Chen HY, Lu SN, Hung CH, Wang JH, Chen CH, Yen YH, Kuo YH, Kee KM. Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation. PLoS One 2020;15:e0242113. [PMID: 33170894 DOI: 10.1371/journal.pone.0242113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
329 Tokumitsu Y, Sakamoto K, Tokuhisa Y, Matsui H, Matsukuma S, Maeda Y, Sakata K, Wada H, Eguchi H, Ogihara H, Fujita Y, Hamamoto Y, Iizuka N, Ueno T, Nagano H. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett 2018;15:4411-22. [PMID: 29556288 DOI: 10.3892/ol.2018.7821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
330 Sun LY, Zhu H, Diao YK, Xing H, Liang L, Li J, Zhou YH, Gu WM, Chen TH, Zeng YY, Pawlik TM, Lau WY, Li C, Shen F, Zhang CW, Yang T. A novel online calculator based on albumin-bilirubin and aspartate transaminase-to-platelet ratio index for predicting postoperative morbidity following hepatectomy for hepatocellular carcinoma. Ann Transl Med 2020;8:1591. [PMID: 33437790 DOI: 10.21037/atm-20-1421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
331 Wen X, Yao M, Lu Y, Chen J, Zhou J, Chen X, Zhang Y, Lu W, Qian X, Zhao J, Zhang L, Ding S, Lu F. Integration of Prealbumin into Child-Pugh Classification Improves Prognosis Predicting Accuracy in HCC Patients Considering Curative Surgery. J Clin Transl Hepatol. 2018;6:377-384. [PMID: 30637214 DOI: 10.14218/jcth.2018.00004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
332 Liu X, Xu H, Zhan M, Niu J. The Potential Effects of Diabetes Mellitus on Liver Fibrosis in Patients with Primary Biliary Cholangitis. Med Sci Monit 2019;25:6174-80. [PMID: 31420961 DOI: 10.12659/MSM.916107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
333 Zhong C, Zhang YF, Huang JH, Xiong CM, Wang ZY, Chen QL, Guo RP. Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study. BMC Cancer 2018;18:643. [PMID: 29879928 DOI: 10.1186/s12885-018-4557-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
334 Wahl DR, Schipper MJ, Parikh ND, Owen D, Lawrence TS. Casual Causality: Does Radiofrequency Ablation Really Prolong Survival After Treatment of Localized Hepatocellular Carcinoma? J Clin Oncol 2018;36:2559-60. [PMID: 29945526 DOI: 10.1200/JCO.2018.78.0882] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
335 Tada T, Kumada T, Toyoda H, Nakamura S, Endo Y, Kaneoka Y, Hiraoka A, Joko K, Hirooka M, Hiasa Y. A validation study of combined resection and ablation therapy for multiple hepatocellular carcinoma. Clin Radiol 2021:S0009-9260(21)00509-2. [PMID: 34789396 DOI: 10.1016/j.crad.2021.10.012] [Reference Citation Analysis]
336 Elshaarawy O, Allam N, Abdelsameea E, Gomaa A, Waked I. Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis. World J Hepatol 2020; 12(3): 99-107 [PMID: 32231763 DOI: 10.4254/wjh.v12.i3.99] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
337 Luo C, Wu W, Wu C, Qiu H, Yuan P, Jiang R, Zhao Q, Gong S, Zhang R, Li J, He J, Liu J, Wang L. Liver dysfunction in idiopathic pulmonary arterial hypertension: prevalence, characteristics and prognostic significance, a retrospective cohort study in China. BMJ Open 2021;11:e045165. [PMID: 34493501 DOI: 10.1136/bmjopen-2020-045165] [Reference Citation Analysis]
338 Li Q, Chen C, Zhang J, Wu H, Qiu Y, Song T, Mao X, He Y, Cheng Z, Zhai W, Li J, Zhang D, Geng Z, Tang Z. Prediction Efficacy of Prognostic Nutritional Index and Albumin-Bilirubin Grade in Patients With Intrahepatic Cholangiocarcinoma After Radical Resection: A Multi-Institutional Analysis of 535 Patients. Front Oncol 2021;11:769696. [PMID: 34956888 DOI: 10.3389/fonc.2021.769696] [Reference Citation Analysis]
339 Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M. Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. Cancers (Basel). 2019;11. [PMID: 31284682 DOI: 10.3390/cancers11070952] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 16.7] [Reference Citation Analysis]
340 De La Pinta Alonso C. Radiation-induced liver disease in the era of SBRT: a review. Expert Rev Gastroenterol Hepatol 2020;14:1195-201. [PMID: 32886888 DOI: 10.1080/17474124.2020.1814744] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
341 Cousins MM, Morris E, Maurino C, Devasia TP, Karnak D, Ray D, Parikh ND, Owen D, Ten Haken RK, Schipper MJ, Lawrence TS, Cuneo KC. TNFR1 and the TNFα axis as a targetable mediator of liver injury from stereotactic body radiation therapy. Transl Oncol 2021;14:100950. [PMID: 33395747 DOI: 10.1016/j.tranon.2020.100950] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
342 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Shimono Y, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Serum Zinc Level Grading System: A Useful Model for Composite Hepatic Events in Hepatitis C Virus-Associated Liver Cirrhosis. J Clin Med 2020;9:E643. [PMID: 32121095 DOI: 10.3390/jcm9030643] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
343 Ye JZ, Mai RY, Guo WX, Wang YY, Ma L, Xiang BD, Cheng SQ, Li LQ. Nomogram for prediction of the international study Group of Liver Surgery (ISGLS) grade B/C Posthepatectomy liver failure in HBV-related hepatocellular carcinoma patients: an external validation and prospective application study. BMC Cancer 2020;20:1036. [PMID: 33115425 DOI: 10.1186/s12885-020-07480-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
344 Wang Y, Pang Q, Jin H, Zhou L, Hu X, Qian Z, Man Z, Yang S, Liu H. Albumin-Bilirubin Grade as a Novel Predictor of Survival in Advanced Extrahepatic Cholangiocarcinoma. Gastroenterol Res Pract 2018;2018:8902146. [PMID: 30622562 DOI: 10.1155/2018/8902146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
345 Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, Shin SW, Chang Y, Kim YJ, Yoon JH, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Dig Dis Sci. 2018;63:1062-1071. [PMID: 29442276 DOI: 10.1007/s10620-018-4934-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
346 Cheng R, Xu J, Tan N, Luo H, Pan J, Xu X. Predictive Nomograms for Clinical Outcomes in Hepatitis B-Related Cirrhosis Patients Receiving Antiviral Therapy. Infect Drug Resist 2021;14:2707-19. [PMID: 34290509 DOI: 10.2147/IDR.S316026] [Reference Citation Analysis]
347 Li W, Han J, Xie G, Xiao Y, Sun K, Yuan K, Wu H. Laparoscopic versus open mesohepatectomy for patients with centrally located hepatocellular carcinoma: a propensity score matched analysis. Surg Endosc 2019;33:2916-26. [PMID: 30498855 DOI: 10.1007/s00464-018-6593-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
348 Bai Y, Wu J, Zeng Y, Chen J, Wang S, Chen S, Qiu F, Zhou S, You S, Tian Y, Wang Y, Yan M. Nomogram for Predicting Long-Term Survival after Synchronous Resection for Hepatocellular Carcinoma and Inferior Vena Cava Tumor Thrombosis: A Multicenter Retrospective Study. J Oncol. 2020;2020:3264079. [PMID: 32322268 DOI: 10.1155/2020/3264079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
349 Maesaka K, Sakamori R, Yamada R, Tahata Y, Imai Y, Ohkawa K, Miyazaki M, Mita E, Ito T, Hagiwara H, Yakushijin T, Kodama T, Hikita H, Tatsumi T, Takehara T. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatol Res 2021. [PMID: 34918428 DOI: 10.1111/hepr.13741] [Reference Citation Analysis]
350 Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Rep 2021;3:100215. [PMID: 33392490 DOI: 10.1016/j.jhepr.2020.100215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
351 Mohammadi H, Abuodeh Y, Jin W, Frakes J, Friedman M, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Hoffe S. Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma. J Gastrointest Oncol. 2018;9:840-846. [PMID: 30505583 DOI: 10.21037/jgo.2018.05.14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
352 Mai RY, Ye JZ, Long ZR, Shi XM, Bai T, Chen J, Li LQ, Wu GB, Wu FX. Preoperative aspartate aminotransferase-to-platelet-ratio index as a predictor of posthepatectomy liver failure for resectable hepatocellular carcinoma. Cancer Manag Res. 2019;11:1401-1414. [PMID: 30863151 DOI: 10.2147/cmar.s186114] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
353 Wang HW, Chuang PH, Su WP, Kao JT, Hsu WF, Lin CC, Huang GT, Lin JT, Lai HC, Peng CY. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3758. [PMID: 34359658 DOI: 10.3390/cancers13153758] [Reference Citation Analysis]
354 Nam JY, Choe AR, Sinn DH, Lee JH, Kim HY, Yu SJ, Kim YJ, Yoon JH, Lee JM, Chung JW, Choi SY, Lee JK, Baek SY, Lee HA, Kim TH, Yoo K. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer 2020;20:504. [PMID: 32487089 DOI: 10.1186/s12885-020-06975-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
355 Okuda T, Hayashi N, Takahashi M, Uzuka T, Okita Y, Otani R, Fujinaka T, Fujita M, Kato A, Narita Y, Nakasu Y. Clinical outcomes of brain metastases from hepatocellular carcinoma: a multicenter retrospective study and a literature review. Int J Clin Oncol. 2018;23:1095-1100. [PMID: 29968168 DOI: 10.1007/s10147-018-1312-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
356 Toshida K, Itoh S, Yoshizumi T, Shimagaki T, Wang H, Kurihara T, Toshima T, Nagao Y, Harada N, Hata K, Makihara Y, Watanabe H, Mori M. Retrospective evaluation of the effect of Ninjin'yoeito in hepatocellular carcinoma patients treated with lenvatinib. Surg Today 2021. [PMID: 34417867 DOI: 10.1007/s00595-021-02358-7] [Reference Citation Analysis]
357 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Serum Zinc Level Classification System: Usefulness in Patients with Liver Cirrhosis. J Clin Med 2019;8:E2057. [PMID: 31766742 DOI: 10.3390/jcm8122057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
358 Bhangoo RS, Mullikin TC, Ashman JB, Cheng TW, Golafshar MA, DeWees TA, Johnson JE, Shiraishi S, Liu W, Hu Y, Merrell KW, Haddock MG, Krishnan S, Rule WG, Sio TT, Hallemeier CL. Intensity Modulated Proton Therapy for Hepatocellular Carcinoma: Initial Clinical Experience. Adv Radiat Oncol 2021;6:100675. [PMID: 34409199 DOI: 10.1016/j.adro.2021.100675] [Reference Citation Analysis]
359 Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma 2021;8:477-92. [PMID: 34079777 DOI: 10.2147/JHC.S251729] [Reference Citation Analysis]
360 Hayashi T, Watanabe T, Shibata M, Kumei S, Oe S, Miyagawa K, Honma Y, Harada M. Endoscopic injection sclerotherapy improves liver function compared with endoscopic variceal ligation. Sci Rep 2021;11:20479. [PMID: 34650156 DOI: 10.1038/s41598-021-99855-z] [Reference Citation Analysis]
361 Li H, Li J, Wang J, Liu H, Cai B, Wang G, Wu H. Assessment of Liver Function for Evaluation of Long-Term Outcomes of Intrahepatic Cholangiocarcinoma: A Multi-Institutional Analysis of 620 Patients. Front Oncol 2020;10:525. [PMID: 32411593 DOI: 10.3389/fonc.2020.00525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
362 Shimada M, Hirashima N, Iwase H, Saito M, Kondo H, Urata N, Unita S, Kondo T, Tanaka D, Tsunekawa T, Fujishiro M. Evaluation of Muscle Cramp Associated with Liver Cirrhosis with a Focus on the Liver Function and Nutritional Status. Intern Med 2021;60:1343-8. [PMID: 33281163 DOI: 10.2169/internalmedicine.6231-20] [Reference Citation Analysis]
363 Zhang CC, Zhang CW, Xing H, Wang Y, Liang L, Diao YK, Chen TH, Lau WY, Bie P, Chen ZY, Yang T. Preoperative Inversed Albumin-to-Globulin Ratio Predicts Worse Oncologic Prognosis Following Curative Hepatectomy for Hepatocellular Carcinoma. Cancer Manag Res 2020;12:9929-39. [PMID: 33116850 DOI: 10.2147/CMAR.S275307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Crane CH, Koay EJ. Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance. Cancer. 2016;122:1974-1986. [PMID: 26950735 DOI: 10.1002/cncr.29878] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
365 Ke L, Shen R, Fan W, Hu W, Shen S, Li S, Kuang M, Liang L, Li J, Peng B, Hua Y. The role of associating liver partition and portal vein ligation for staged hepatectomy in unresectable hepatitis B virus-related hepatocellular carcinoma. Ann Transl Med 2020;8:1402. [PMID: 33313147 DOI: 10.21037/atm-20-2420] [Reference Citation Analysis]
366 Saeki I, Yamasaki T, Yamashita S, Hanazono T, Urata Y, Furutani T, Yokoyama Y, Oishi T, Maeda M, Kimura T, Kotoh Y, Sasaki R, Miyaji T, Oono T, Aibe Y, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment. Cancers (Basel) 2020;12:E779. [PMID: 32218295 DOI: 10.3390/cancers12040779] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
367 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
368 Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020;8:e001072. [PMID: 32863270 DOI: 10.1136/jitc-2020-001072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
369 Pursley J, El Naqa I, Sanford NN, Noe B, Wo JY, Eyler CE, Hwang M, Brock KK, Yeap BY, Wolfgang JA, Hong TS, Grassberger C. Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation. Int J Radiat Oncol Biol Phys 2020;107:986-95. [PMID: 32353390 DOI: 10.1016/j.ijrobp.2020.04.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
370 Yang Y, Ye F, Xin Y, Wang Y, Li X, Feng D, Chen Y, Zhou X. Prognostic significance of controlling nutritional status score-based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation. J Gastrointest Oncol 2020;11:1024-39. [PMID: 33209495 DOI: 10.21037/jgo-20-225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
371 Shinozaki S, Tahara T, Lefor AK, Ogura M. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. Clin Exp Hepatol 2021;7:172-7. [PMID: 34295984 DOI: 10.5114/ceh.2021.106864] [Reference Citation Analysis]
372 Pan J, Chen S, Tian G, Jiang T. Preoperative Albumin-Bilirubin Grade With Prognostic Nutritional Index Predicts the Outcome of Patients With Early-Stage Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation. Front Med (Lausanne) 2020;7:584871. [PMID: 33240907 DOI: 10.3389/fmed.2020.584871] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
373 Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer 2019;8:121-9. [PMID: 31019902 DOI: 10.1159/000488778] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 11.3] [Reference Citation Analysis]
374 Xiao H, Li JL, Chen SL, Tang MM, Zhou Q, Wu TF, Li X, Peng ZW, Feng ST, Peng S, Kuang M. A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. Front Oncol 2021;11:569515. [PMID: 33718130 DOI: 10.3389/fonc.2021.569515] [Reference Citation Analysis]
375 Zhong W, Zhang F, Huang K, Zou Y, Liu Y. Development and Validation of a Nomogram Based on Noninvasive Liver Reserve and Fibrosis (PALBI and FIB-4) Model to Predict Posthepatectomy Liver Failure Grade B-C in Patients with Hepatocellular Carcinoma. J Oncol 2021;2021:6665267. [PMID: 34221013 DOI: 10.1155/2021/6665267] [Reference Citation Analysis]
376 Ohashi K, Ishikawa T, Hoshii A, Hokari T, Noguchi H, Suzuki M, Hirosawa H, Imai M, Mitobe Y, Yoshida T. Optimal Skeletal Muscle Mass Index Cut-Off Values for Presarcopenia Evaluated by Computed Tomography against Dual-Energy X-ray Absorptiometry in Patients with Chronic Liver Disease. J Clin Med 2021;10:1419. [PMID: 33915929 DOI: 10.3390/jcm10071419] [Reference Citation Analysis]
377 Liao X, Zhao S, Yin J, Liu L, Liang J, Jiang Y, Yu N, Fan R, Zhong C. Sexual Dysfunction in Patients with Chronic Hepatitis B: Prevalence and Risk Factors. J Sex Med 2021:S1743-6095(21)00792-X. [PMID: 34969615 DOI: 10.1016/j.jsxm.2021.11.016] [Reference Citation Analysis]
378 Kokudo T, Hasegawa K. Evaluating the liver function of patients with hepatocellular carcinoma. Hepatol Res 2021;51:1095-6. [PMID: 34724293 DOI: 10.1111/hepr.13705] [Reference Citation Analysis]
379 Ogasawara S, Chiba T, Ooka Y, Suzuki E, Kanogawa N, Saito T, Motoyama T, Tawada A, Kanai F, Yokosuka O. Liver function assessment according to the Albumin–Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Invest New Drugs 2015;33:1257-62. [DOI: 10.1007/s10637-015-0292-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
380 Zhu C, Wang X, Yang X, Sun J, Pan B, Zhang W, Chen X, Shen X. Preoperative Albumin-Bilirubin Grade as a Prognostic Predictor in Colorectal Cancer Patients Who Undergo Radical Resection. Cancer Manag Res 2020;12:12363-74. [PMID: 33293863 DOI: 10.2147/CMAR.S285212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
381 Yoh T, Seo S. ASO Author Reflections: Proposal of a New Preoperative Prognostic Model for Solitary Hepatocellular Carcinoma. Ann Surg Oncol 2018;25:780-1. [PMID: 30264250 DOI: 10.1245/s10434-018-6796-8] [Reference Citation Analysis]
382 Dong ZR, Zou J, Sun D, Shi GM, Ke AW, Cai JB, Sun HC, Qiu SJ, Li T, Zhou J, Zhi XT, Fan J. Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. J Cancer. 2017;8:3862-3867. [PMID: 29151974 DOI: 10.7150/jca.21313] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
383 Beer L, Mandorfer M, Bastati N, Poetter-Lang S, Tamandl D, Stoyanova DP, Elmer MC, Semmler G, Simbrunner B, Hodge JC, Sirlin CB, Reiberger T, Ba-Ssalamah A. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 2019;29:6600-10. [PMID: 31001679 DOI: 10.1007/s00330-019-06182-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
384 Shen X, Wang W, Niu X. Neutrophil Lymphocyte Ratio to Albumin Ratio and White Blood Cell to Hemoglobin Ratio as Prognostic Markers for Hepatocellular Carcinoma Patients Who Underwent Curative Hepatectomy. Int J Gen Med 2021;14:5029-38. [PMID: 34511986 DOI: 10.2147/IJGM.S329911] [Reference Citation Analysis]
385 Huang C, Fang M, Xiao X, Wang H, Gao Z, Ji J, Liu L, Gu E, Li Y, Wang M, Gao C. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study. Liver Int 2021. [PMID: 34679250 DOI: 10.1111/liv.15082] [Reference Citation Analysis]
386 Xing Y, Liu ZR, Yu W, Zhang HY, Song MM. Risk factors for post-hepatectomy liver failure in 80 patients. World J Clin Cases 2021; 9(8): 1793-1802 [PMID: 33748228 DOI: 10.12998/wjcc.v9.i8.1793] [Reference Citation Analysis]
387 Terashima T, Yamashita T, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. Liver Cancer. 2017;6:236-249. [PMID: 28626734 DOI: 10.1159/000472262] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
388 Nagaoki Y, Hyogo H, Ando Y, Kosaka Y, Uchikawa S, Nishida Y, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Okamoto W, Kawaoka T, Tsuge M, Hiramatsu A, Miki D, Imamura M, Takahashi S, Chayama K, Aikata H. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. BMC Gastroenterol 2021;21:306. [PMID: 34332532 DOI: 10.1186/s12876-021-01884-5] [Reference Citation Analysis]
389 Zhang W, Zhangyuan G, Wang F, Zhang H, Yu D, Wang J, Jin K, Yu W, Liu Y, Sun B. High preoperative serum globulin in hepatocellular carcinoma is a risk factor for poor survival. J Cancer 2019;10:3494-500. [PMID: 31293654 DOI: 10.7150/jca.29499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
390 Lu S, Yao Y, Xu G, Zhou C, Zhang Y, Sun J, Jiang R, Shao Q, Chen Y. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis. 2018;9:646. [PMID: 29844385 DOI: 10.1038/s41419-018-0681-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
391 Finkelmeier F, Canli Ö, Peiffer KH, Walter D, Tal A, Koch C, Pession U, Vermehren J, Trojan J, Zeuzem S, Piiper A, Greten FR, Grammatikos G, Waidmann O. Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis. PLoS One 2018;13:e0200855. [PMID: 30011326 DOI: 10.1371/journal.pone.0200855] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
392 Jaruvongvanich V, Sempokuya T, Wong L. Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma? J Gastrointest Oncol 2018;9:750-61. [PMID: 30151272 DOI: 10.21037/jgo.2018.05.11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
393 Lee KH, Yu JI, Park HC, Park SY, Shin JS, Shin EH, Cho S, Jung SH, Han YY, Lim DH. Is higher dose always the right answer in stereotactic body radiation therapy for small hepatocellular carcinoma? Radiat Oncol J. 2018;36:129-138. [PMID: 29983033 DOI: 10.3857/roj.2017.00598] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
394 Hirooka M, Koizumi Y, Tanaka T, Sunago K, Nakamura Y, Watanabe T, Yoshida O, Tokumoto Y, Abe M, Hiasa Y. Radiofrequency Ablation Covering the Entire Tumor Blood Drainage Area Improves Survival in Hepatocellular Carcinoma. Hepatol Commun 2021;5:1300-9. [PMID: 34278177 DOI: 10.1002/hep4.1703] [Reference Citation Analysis]
395 Sato S, Amano N, Sato S, Kita Y, Ikeda Y, Kabemura D, Murata A, Yatagai N, Tsuzura H, Shimada Y, Genda T. Elevated serum tyrosine concentration is associated with a poor prognosis among patients with liver cirrhosis. Hepatol Res 2021;51:786-95. [PMID: 33964118 DOI: 10.1111/hepr.13651] [Reference Citation Analysis]
396 Öcal O, Peynircioglu B, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Iezzi R, Benito A, Schütte K, Gasbarrini A, Seidensticker R, Wildgruber M, Pech M, Malfertheiner P, Ricke J, Seidensticker M. Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. Eur Radiol 2021. [PMID: 34467453 DOI: 10.1007/s00330-021-08218-9] [Reference Citation Analysis]
397 Fan Y, Yu Y, Hu M, Wang X, Du M, Guo L, Hu C. Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma. Br J Radiol 2021;94:20200950. [PMID: 33417489 DOI: 10.1259/bjr.20200950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
398 Shi JY, Wang NY. Is ALPlat criterion justified for predicting posthepatectomy liver failure? Surgery 2020;168:1180. [PMID: 32682506 DOI: 10.1016/j.surg.2020.05.034] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
399 Xu W, Liu F, Shen X, Li R. Prognostic Nomograms for Patients with Hepatocellular Carcinoma After Curative Hepatectomy, with a Focus on Recurrence Timing and Post-Recurrence Management. J Hepatocell Carcinoma 2020;7:233-56. [PMID: 33154956 DOI: 10.2147/JHC.S271498] [Reference Citation Analysis]
400 Tanemura A, Mizuno S, Hayasaki A, Gyoten K, Fujii T, Iizawa Y, Kato H, Murata Y, Kuriyama N, Kishiwada M, Sakurai H, Isaji S. Onodera's prognostic nutritional index is a strong prognostic indicator for patients with hepatocellular carcinoma after initial hepatectomy, especially patients with preserved liver function. BMC Surg 2020;20:261. [PMID: 33129309 DOI: 10.1186/s12893-020-00917-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
401 Ishikawa T, Endo S, Imai M, Azumi M, Nozawa Y, Sano T, Iwanaga A, Honma T, Yoshida T. Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy. Intern Med 2020;59:2465-9. [PMID: 33055469 DOI: 10.2169/internalmedicine.5094-20] [Reference Citation Analysis]
402 El Dika I, Makki I, Abou-Alfa GK. Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol 2021;10:12. [PMID: 32527116 DOI: 10.21037/cco-20-113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
403 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
404 Zhao J, Chen Y, Wang J, Wang J, Wang Y, Chai S, Zhang Y, Chen X, Zhang W. Preoperative risk grade predicts the long-term prognosis of intrahepatic cholangiocarcinoma: a retrospective cohort analysis. BMC Surg 2021;21:113. [PMID: 33676467 DOI: 10.1186/s12893-020-00954-x] [Reference Citation Analysis]
405 Ho CHM, Chiang CL, Lee FAS, Choi HCW, Chan JCH, Yeung CSY, Huang JJ, Chan MKH, Blanck O, Wong FCS. Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and child-pugh (CP) score for predicting of survival in advanced hcc patients receiving radiotherapy (RT). Oncotarget 2018;9:28818-29. [PMID: 29988960 DOI: 10.18632/oncotarget.25522] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
406 Zou H, Tao Y, Wang ZM. Integration of Child-Pugh score with future liver remnant yields improved prediction of liver dysfunction risk for HBV-related hepatocellular carcinoma following hepatic resection. Oncol Lett. 2017;13:3631-3637. [PMID: 28521464 DOI: 10.3892/ol.2017.5919] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
407 Li S, Han X, Lyu N, Xie Q, Deng H, Mu L, Pan T, Huang X, Wang X, Shi Y, Zhao M. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma. Cancer Sci 2018;109:3726-36. [PMID: 30264546 DOI: 10.1111/cas.13811] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
408 Ye L, Liang R, Zhang J, Chen C, Chen X, Zhang Y, Wang G, Yang Y, Chen G. Postoperative albumin-bilirubin grade and albumin-bilirubin change predict the outcomes of hepatocellular carcinoma after hepatectomy. Ann Transl Med. 2019;7:367. [PMID: 31555681 DOI: 10.21037/atm.2019.06.01] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
409 Suwa K, Seki T, Aoi K, Yamashina M, Murata M, Yamashiki N, Nishio A, Shimatani M, Naganuma M. Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis. Abdom Radiol (NY) 2021;46:3790-7. [PMID: 33675382 DOI: 10.1007/s00261-021-03008-9] [Reference Citation Analysis]
410 Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer. 2015;4:126-136. [PMID: 26020034 DOI: 10.1159/000367735] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 7.7] [Reference Citation Analysis]
411 Ieda S, Miyamoto T, Hosomi K, Takegami M, Kawabata A. Identification of Remaining Life Expectancy Less Than Two Weeks by C-Reactive Protein/Albumin Ratio, Prognostic Nutritional Index, Fibrosis-4 Index, and Albumin-Bilirubin Score in Terminal Cancer Patients. J Palliat Med 2021. [PMID: 34612718 DOI: 10.1089/jpm.2021.0243] [Reference Citation Analysis]
412 van Doorn DJ, Hendriks P, Burgmans MC, Rietbergen DDD, Coenraad MJ, van Delden OM, Bennink RJ, Labeur TA, Klümpen HJ, Eskens FALM, Moelker A, Vegt E, Sprengers D, Mostafavi N, Ijzermans J, Takkenberg RB. Liver Decompensation as Late Complication in HCC Patients with Long-Term Response following Selective Internal Radiation Therapy. Cancers (Basel) 2021;13:5427. [PMID: 34771591 DOI: 10.3390/cancers13215427] [Reference Citation Analysis]
413 Kong W, Gao M, Jin Y, Huang W, Huang Z, Xie Z. Prognostic model of patients with liver cancer based on tumor stem cell content and immune process. Aging (Albany NY) 2020;12:16555-78. [PMID: 32852285 DOI: 10.18632/aging.103832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
414 Qiu Y, Wang T, Yang X, Shen S, Yang Y, Wang W. Development and Validation of Artificial Neural Networks for Survival Prediction Model for Patients with Spontaneous Hepatocellular Carcinoma Rupture After Transcatheter Arterial Embolization. Cancer Manag Res 2021;13:7463-77. [PMID: 34611440 DOI: 10.2147/CMAR.S328307] [Reference Citation Analysis]
415 Kokudo T, Hasegawa K, Amikura K, Uldry E, Shirata C, Yamaguchi T, Arita J, Kaneko J, Akamatsu N, Sakamoto Y, Takahashi A, Sakamoto H, Makuuchi M, Matsuyama Y, Demartines N, Malagó M, Kokudo N, Halkic N. Assessment of Preoperative Liver Function in Patients with Hepatocellular Carcinoma - The Albumin-Indocyanine Green Evaluation (ALICE) Grade. PLoS One 2016;11:e0159530. [PMID: 27434062 DOI: 10.1371/journal.pone.0159530] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
416 Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med 2019;8:3719-28. [PMID: 31127698 DOI: 10.1002/cam4.2241] [Cited by in Crossref: 39] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
417 Tsuchiya K, Kurosaki M, Sakamoto A, Marusawa H, Kojima Y, Hasebe C, Arai H, Joko K, Kondo M, Tsuji K, Sohda T, Kimura H, Ogawa C, Uchida Y, Wada S, Kobashi H, Furuta K, Shigeno M, Kusakabe A, Akahane T, Narita R, Yoshida H, Mitsuda A, Ide Y, Matsushita T, Izumi N, On Behalf Of Japanese Red Cross Liver Study Group. The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers (Basel) 2021;13:2608. [PMID: 34073396 DOI: 10.3390/cancers13112608] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
418 Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Zhu XL, Wen L, Ni CF. Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Mol Biosci 2021;8:618050. [PMID: 34095216 DOI: 10.3389/fmolb.2021.618050] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
419 Jackson WC, Suresh K, Maurino C, Feng M, Cuneo KC, Ten Haken RK, Lawrence TS, Schipper MJ, Owen D. A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy. Radiother Oncol 2019;141:101-7. [PMID: 31431377 DOI: 10.1016/j.radonc.2019.07.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
420 Hiraoka A, Kumada T, Kariyama K, Tada T, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. J Gastroenterol Hepatol 2021;36:1812-9. [PMID: 33171524 DOI: 10.1111/jgh.15336] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
421 Hoshi H, Chu PS, Yoshida A, Taniki N, Morikawa R, Yamataka K, Noguchi F, Kasuga R, Tabuchi T, Ebinuma H, Saito H, Kanai T, Nakamoto N. Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis. PLoS One 2021;16:e0250062. [PMID: 33848309 DOI: 10.1371/journal.pone.0250062] [Reference Citation Analysis]
422 Lee HA, Park S, Seo YS, Yoon WS, Rim CH, On Behalf Of The Korean Liver Cancer Study Group. Benefits of Local Treatment Including External Radiotherapy for Hepatocellular Carcinoma with Portal Invasion. Biology (Basel) 2021;10:326. [PMID: 33919745 DOI: 10.3390/biology10040326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Kim N, Seong J. Reply to: "Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers". J Hepatol 2020;73:973-4. [PMID: 32646619 DOI: 10.1016/j.jhep.2020.05.031] [Reference Citation Analysis]
424 Hatanaka T, Kosone T, Saito N, Takakusagi S, Tojima H, Naganuma A, Takagi H, Uraoka T, Kakizaki S. Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score. JGH Open 2021;5:1183-9. [PMID: 34622006 DOI: 10.1002/jgh3.12650] [Reference Citation Analysis]
425 Casadei Gardini A, Marisi G, Canale M, Foschi FG, Donati G, Ercolani G, Valgiusti M, Passardi A, Frassineti GL, Scarpi E. Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. Onco Targets Ther 2018;11:6555-67. [PMID: 30323628 DOI: 10.2147/OTT.S170836] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
426 Hayakawa Y, Tsuchiya K, Kurosaki M, Yasui Y, Kaneko S, Tanaka Y, Ishido S, Inada K, Kirino S, Yamashita K, Nobusawa T, Matsumoto H, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Izumi N. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. Invest New Drugs 2021. [PMID: 34586531 DOI: 10.1007/s10637-021-01185-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
427 Tokumitsu Y, Shindo Y, Matsui H, Matsukuma S, Nakajima M, Suzuki N, Takeda S, Wada H, Kobayashi S, Eguchi H, Ueno T, Nagano H. Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy. Oncol Lett 2019;18:3903-13. [PMID: 31516601 DOI: 10.3892/ol.2019.10688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
428 Gui B, Weiner AA, Nosher J, Lu SE, Foltz GM, Hasan O, Kim SK, Gendel V, Mani NB, Carpizo DR, Saad NE, Kennedy TJ, Zuckerman DA, Olsen JR, Parikh PJ, Jabbour SK. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization. Am J Clin Oncol. 2018;41:861-866. [PMID: 28418940 DOI: 10.1097/coc.0000000000000384] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
429 Ho SY, Hsu CY, Liu PH, Ko CC, Huang YH, Su CW, Lee RC, Hou MC, Huo TI. Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. Cancers (Basel) 2020;12:E1130. [PMID: 32366000 DOI: 10.3390/cancers12051130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
430 Stemmer SM, Manojlovic NS, Marinca MV, Petrov P, Cherciu N, Ganea D, Ciuleanu TE, Pusca IA, Beg MS, Purcell WT, Croitoru AE, Ilieva RN, Natošević S, Nita AL, Kalev DN, Harpaz Z, Farbstein M, Silverman MH, Bristol D, Itzhak I, Fishman P. Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. Cancers (Basel) 2021;13:E187. [PMID: 33430312 DOI: 10.3390/cancers13020187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
431 Vogeler M, Mohr I, Pfeiffenberger J, Sprengel SD, Klauss M, Teufel A, Chang DH, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. J Cancer Res Clin Oncol 2020;146:1033-50. [PMID: 32107625 DOI: 10.1007/s00432-020-03135-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
432 Kwee SA, Wong L, Chan OTM, Kalathil S, Tsai N. PET/CT with 18F Fluorocholine as an Imaging Biomarker for Chronic Liver Disease: A Preliminary Radiopathologic Correspondence Study in Patients with Liver Cancer. Radiology 2018;287:294-302. [PMID: 29315063 DOI: 10.1148/radiol.2018171333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
433 Zhang J, Xu Q, Zhang H, Zhang Y, Yang Y, Luo H, Lin X, He X, Mou Y, Zhou Z, He Z. High preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas. Transl Oncol 2021;14:101038. [PMID: 33596518 DOI: 10.1016/j.tranon.2021.101038] [Reference Citation Analysis]
434 Hiraoka A, Kumada T, Tada T, Ogawa C, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Toyoda H, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular-carcinoma experts from 48 clinics in Japan). Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2021;9:133-8. [PMID: 34026220 DOI: 10.1093/gastro/goaa042] [Reference Citation Analysis]
435 Hung YW, Lee IC, Chi CT, Lee RC, Liu CA, Chiu NC, Hwang HE, Chao Y, Hou MC, Huang YH. Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. Liver Cancer 2021;10:629-40. [PMID: 34950185 DOI: 10.1159/000517393] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Liang X, Liangliang X, Peng W, Tao Y, Jinfu Z, Ming Z, Mingqing X. Combined prognostic nutritional index and albumin-bilirubin grade to predict the postoperative prognosis of HBV-associated hepatocellular carcinoma patients. Sci Rep 2021;11:14624. [PMID: 34272447 DOI: 10.1038/s41598-021-94035-5] [Reference Citation Analysis]
437 Adhoute X, Larrey E, Anty R, Chevallier P, Penaranda G, Tran A, Bronowicki JP, Raoul JL, Castellani P, Perrier H, Bayle O, Monnet O, Pol B, Bourliere M. Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results. World J Clin Cases 2021; 9(18): 4559-4572 [PMID: 34222423 DOI: 10.12998/wjcc.v9.i18.4559] [Reference Citation Analysis]
438 Li S, Zhang X, Li Q, Lv B, Zhang Y, Jia J, Yue X, Lu W. Development and validation of the nomogram based on INR and eGFR for estimation of mortality in patients with acute-on-chronic hepatitis B liver failure. BMC Gastroenterol 2021;21:474. [PMID: 34911462 DOI: 10.1186/s12876-021-02054-3] [Reference Citation Analysis]
439 Zhang K, Tao C, Siqin T, Wu J, Rong W. Establishment, validation and evaluation of predictive model for early relapse after R0 resection in hepatocellular carcinoma patients with microvascular invasion. J Transl Med 2021;19:293. [PMID: 34229698 DOI: 10.1186/s12967-021-02940-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
440 Shigefuku R, Iwasa M, Eguchi A, Tempaku M, Tamai Y, Suzuki T, Takei Y. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites. Intern Med 2021;60:3359-68. [PMID: 34719623 DOI: 10.2169/internalmedicine.7291-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
442 Zhu C, Wang X, Chen S, Yang X, Sun J, Pan B, Zhang W, Chen X, Huang Y. Efficacy of the Preoperative Albumin-Bilirubin Grade for Predicting Survival and Outcomes of Postoperative Chemotherapy for Advanced Gastric Cancer. Cancer Manag Res 2020;12:11921-32. [PMID: 33244269 DOI: 10.2147/CMAR.S279782] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
443 Labeur TA, Berhane S, Edeline J, Blanc JF, Bettinger D, Meyer T, Van Vugt JLA, Ten Cate DWG, De Man RA, Eskens FALM, Cucchetti A, Bonnett LJ, Van Delden OM, Klümpen HJ, Takkenberg RB, Johnson PJ. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver Int 2020;40:215-28. [PMID: 31579990 DOI: 10.1111/liv.14270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
444 Zhang X, Zhang X, Li X, Bao H, Li G, Li N, Li H, Dou J. Connection Between CDC20 Expression and Hepatocellular Carcinoma Prognosis. Med Sci Monit 2021;27:e926760. [PMID: 33788826 DOI: 10.12659/MSM.926760] [Reference Citation Analysis]
445 Waked I, Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, Mo F, Bettinger D, Kirstein MM, Iñarrairaegui M, Gomaa A, Vogel A, Meyer T, Sangro B, Lai P, Kumada T, Johnson PJ. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer 2017;116:448-54. [PMID: 28125820 DOI: 10.1038/bjc.2016.423] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
446 Jing CY, Fu YP, Shen HJ, Zheng SS, Lin JJ, Yi Y, Huang JL, Xu X, Zhang J, Zhou J, Fan J, Ren ZG, Qiu SJ, Zhang BH. Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. Oncotarget. 2017;8:13293-13303. [PMID: 28076328 DOI: 10.18632/oncotarget.14530] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
447 Takada H, Kurosaki M, Tsuchiya K, Komiyama Y, Itakura J, Takahashi Y, Nakanishi H, Yasui Y, Tamaki N, Maeyashiki C, Kaneko S, Takaura K, Higuchi M, Okada M, Wang W, Osawa L, Sekiguchi S, Hayakawa Y, Yamashita K, Enomoto N, Izumi N. Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31461985 DOI: 10.3390/cancers11091256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
448 Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J. Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma 2021;8:837-50. [PMID: 34350139 DOI: 10.2147/JHC.S308587] [Reference Citation Analysis]
449 Yang ZW, He W, Zheng Y, Zou RH, Liu WW, Zhang YP, Wang CW, Wang YJ, Yuan YC, Li BK, Yuan YF. The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma. J Cancer 2018;9:4000-8. [PMID: 30410605 DOI: 10.7150/jca.24250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
450 Ji GW, Zhu FP, Xu Q, Wang K, Wu MY, Tang WW, Li XC, Wang XH. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: A multi-institutional study. EBioMedicine 2019;50:156-65. [PMID: 31735556 DOI: 10.1016/j.ebiom.2019.10.057] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
451 Lambrecht J, Porsch-Özçürümez M, Best J, Jost-Brinkmann F, Roderburg C, Demir M, Tacke F, Mohr R. The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. J Clin Med 2021;10:3392. [PMID: 34362181 DOI: 10.3390/jcm10153392] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
452 Hoffman DH, Ayoola A, Nickel D, Han F, Chandarana H, Babb J, Shanbhogue KP. MR elastography, T1 and T2 relaxometry of liver: role in noninvasive assessment of liver function and portal hypertension. Abdom Radiol (NY) 2020;45:2680-7. [PMID: 32274552 DOI: 10.1007/s00261-020-02432-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
453 Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, Manas D, Shah T, Newsome PN, Reeves H, Shetty S. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73-81. [PMID: 27634970 DOI: 10.1093/qjmed/hcw151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
454 Matei D, Craciun R, Crisan D, Procopet B, Mocan T, Pasca S, Zaharie R, Popovici B, Sparchez Z. Hepatic Hydrothorax-An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis. J Clin Med 2021;10:3688. [PMID: 34441984 DOI: 10.3390/jcm10163688] [Reference Citation Analysis]
455 Shirata C, Hasegawa K. Albumin-indocyanine green evaluation model in Western population. J Hepatobiliary Pancreat Sci 2019;26:E7. [PMID: 31240837 DOI: 10.1002/jhbp.651] [Reference Citation Analysis]
456 Tian MX, Liu WR, Wang H, Zhou YF, Jin L, Jiang XF, Tao CY, Tang Z, Zhou PY, Fang Y, Qu WF, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Lau WY, Fan J, Shi YH. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Med 2019;17:106. [PMID: 31164128 DOI: 10.1186/s12916-019-1341-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
457 Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021;14:17562848211016959. [PMID: 34104211 DOI: 10.1177/17562848211016959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
458 Kawaguchi T, Honda A, Sugiyama Y, Nakano D, Tsutsumi T, Tahara N, Torimura T, Fukumoto Y. Association between the albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data-mining analysis. Hepatol Res 2021;51:1207-18. [PMID: 34534392 DOI: 10.1111/hepr.13714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
459 Chen S, Ma W, Cao F, Shen L, Qi H, Xie L, Wu Y, Fan W. Hepatocellular Carcinoma Within the Milan Criteria: A Novel Inflammation-Based Nomogram System to Assess the Outcomes of Ablation. Front Oncol 2020;10:1764. [PMID: 33042823 DOI: 10.3389/fonc.2020.01764] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
460 Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R, Murakami S, Yano S, Amioka K, Naruto K, Kosaka Y, Uchikawa S, Kodama K, Fujino H, Nakahara T, Ono A, Murakami E, Yamauchi M, Okamoto W, Takahashi S, Imamura M, Chayama K, Aikata H. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. Cancers (Basel) 2021;13:3958. [PMID: 34439111 DOI: 10.3390/cancers13163958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
461 Mori H, Machimura H, Iwaya A, Baba M, Furuya K. Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests. Sci Rep 2021;11:22472. [PMID: 34795343 DOI: 10.1038/s41598-021-01815-0] [Reference Citation Analysis]
462 Piñero F, da Fonseca LG. Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups? World J Gastroenterol 2021; 27(24): 3429-3439 [PMID: 34239261 DOI: 10.3748/wjg.v27.i24.3429] [Reference Citation Analysis]
463 Jahangiri Y, Kerrigan T, Li L, Prosser D, Brar A, Righetti J, Schenning RC, Kaufman JA, Farsad K. Risk factors for stent graft thrombosis after transjugular intrahepatic portosystemic shunt creation. Cardiovasc Diagn Ther. 2017;7:S150-S158. [PMID: 29399518 DOI: 10.21037/cdt.2017.10.03] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
464 Nakajima T, Karino Y, Hige S, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y, Toyota J. Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection. Ann Hepatol 2021;27:100566. [PMID: 34688887 DOI: 10.1016/j.aohep.2021.100566] [Reference Citation Analysis]
465 D'Avola D, Granito A, de la Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma. J Hepatol 2021:S0168-8278(21)02185-1. [PMID: 34793869 DOI: 10.1016/j.jhep.2021.11.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Pang Q, Zhou S, Liu S, Liu H, Lu Z. Prognostic role of preoperative albumin-bilirubin score in posthepatectomy liver failure and mortality: a systematic review and meta-analysis. Updates Surg 2021. [PMID: 34013432 DOI: 10.1007/s13304-021-01080-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
467 Li C, Zhang XY, Peng W, Wen TF, Yan LN, Li B, Yang JY, Wang WT, Xu MQ, Chen LP. Preoperative albumin-bilirubin grade plus platelet-to-lymphocyte ratio predict the outcomes of patients with BCLC stage A hepatocellular carcinoma after liver resection. Medicine (Baltimore). 2018;97:e11599. [PMID: 30024565 DOI: 10.1097/md.0000000000011599] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
468 Lee IC, Huang JY, Chen TC, Yen CH, Chiu NC, Hwang HE, Huang JG, Liu CA, Chau GY, Lee RC, Hung YP, Chao Y, Ho SY, Huang YH. Evolutionary Learning-Derived Clinical-Radiomic Models for Predicting Early Recurrence of Hepatocellular Carcinoma after Resection. Liver Cancer 2021;10:572-82. [PMID: 34950180 DOI: 10.1159/000518728] [Reference Citation Analysis]
469 Eguchi A, Hasegawa H, Iwasa M, Tamai Y, Ohata K, Oikawa T, Sugaya T, Takei Y. Serum Liver-Type Fatty Acid-Binding Protein Is a Possible Prognostic Factor in Human Chronic Liver Diseases From Chronic Hepatitis to Liver Cirrhosis and Hepatocellular Carcinoma. Hepatol Commun. 2019;3:825-837. [PMID: 31168516 DOI: 10.1002/hep4.1350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
470 Bowen SR, Chapman TR, Borgman J, Miyaoka RS, Kinahan PE, Liou IW, Sandison GA, Vesselle HJ, Nyflot MJ, Apisarnthanarax S. Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients. EJNMMI Res. 2016;6:57. [PMID: 27349530 DOI: 10.1186/s13550-016-0212-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
471 Vitale A, Farinati F, Finotti M, Di Renzo C, Brancaccio G, Piscaglia F, Cabibbo G, Caturelli E, Missale G, Marra F, Sacco R, Giannini EG, Trevisani F, Cillo U, Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group, Italian Liver Cancer Ita Li Ca Study Group. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers (Basel) 2021;13:1673. [PMID: 33918125 DOI: 10.3390/cancers13071673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Nishikawa H, Yoh K, Enomoto H, Iwata Y, Sakai Y, Kishino K, Shimono Y, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Koriyama T, Yuri Y, Nishimura T, Nishiguchi S, Iijima H. Health-Related Quality of Life and Frailty in Chronic Liver Diseases. Life (Basel) 2020;10:E76. [PMID: 32456292 DOI: 10.3390/life10050076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
473 Zaizen Y, Nakano M, Fukumori K, Yano Y, Takaki K, Niizeki T, Kuwaki K, Fukahori M, Sakaue T, Yoshimura S, Nakazaki M, Kuromatsu R, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T. Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:5282. [PMID: 34771452 DOI: 10.3390/cancers13215282] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
474 Hiraoka A, Kumada T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M. What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure? Liver Cancer 2021;10:115-25. [PMID: 33977088 DOI: 10.1159/000513355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
475 Pang Q, Liu S, Wang L, Pan H, Wang C, Zhou L, Lu Y, Liu H. The Significance of Platelet-Albumin-Bilirubin (PALBI) Grade in Hepatocellular Carcinoma Patients Stratified According to Platelet Count. Cancer Manag Res 2020;12:12811-22. [PMID: 33364830 DOI: 10.2147/CMAR.S277013] [Reference Citation Analysis]
476 Wu J, Mao W. Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases. Dis Markers 2020;2020:2471252. [PMID: 32774512 DOI: 10.1155/2020/2471252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
477 Yang S, Zhou Y, Zhang X, Wang L, Fu J, Zhao X, Yang L. The prognostic value of an autophagy-related lncRNA signature in hepatocellular carcinoma. BMC Bioinformatics 2021;22:217. [PMID: 33910497 DOI: 10.1186/s12859-021-04123-6] [Reference Citation Analysis]
478 Shen YN, Tang TY, Yao WY, Guo CX, Yi-Zong, Song W, Liang TB, Bai XL. A nomogram for prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma: A retrospective study. Medicine (Baltimore) 2019;98:e18490. [PMID: 31861033 DOI: 10.1097/MD.0000000000018490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
479 Iizuka A, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H, Tanaka C, Kobayashi D, Fujiwara M, Murotani K, Kodera Y. Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of S-1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multi-Institutional Dataset Analysis. World J Surg 2019;43:2016-24. [PMID: 30737551 DOI: 10.1007/s00268-019-04942-y] [Reference Citation Analysis]
480 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6:325-336. [PMID: 29234636 DOI: 10.1159/000479984] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 12.8] [Reference Citation Analysis]
481 Cai XR, Chen ZH, Liu MM, Lin JX, Zhang XP, Chen J, Lin Q, Ma XK, Wen JY, Xie SD, Wu XY, Dong M. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. J Cancer. 2018;9:2380-2388. [PMID: 30026834 DOI: 10.7150/jca.22925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
482 Andreatos N, Amini N, Gani F, Margonis GA, Sasaki K, Thompson VM, Bentrem DJ, Hall BL, Pitt HA, Wilson A, Pawlik TM. Albumin-Bilirubin Score: Predicting Short-Term Outcomes Including Bile Leak and Post-hepatectomy Liver Failure Following Hepatic Resection. J Gastrointest Surg. 2017;21:238-248. [PMID: 27619809 DOI: 10.1007/s11605-016-3246-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
483 Fan W, Liao W, Luo Y, You B, Yu J, Li C. Clinical prediction for outcomes of patients with acute-on-chronic liver failure associated with HBV infection: A new model establishment. Open Med (Wars) 2020;15:714-22. [PMID: 33336028 DOI: 10.1515/med-2020-0207] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
484 Rong W, Yu W, Wang L, Wu F, Zhang K, Chen B, Miao C, Liu L, An S, Tao C, Wang W, Wu J. Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy: A 10-year real-world evidence. Chin J Cancer Res 2020;32:645-53. [PMID: 33223759 DOI: 10.21147/j.issn.1000-9604.2020.05.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
485 Kim JH, Kang SH, Lee M, Youn GS, Kim TS, Jun BG, Kim MY, Kim YD, Cheon GJ, Kim DJ, Baik SK, Choi DH, Suk KT. Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study. Cancers (Basel) 2020;12:E3347. [PMID: 33198216 DOI: 10.3390/cancers12113347] [Reference Citation Analysis]
486 Liu LX, Zhang Y, Nie Y, Zhu X. Assessing the Prediction Effect of Various Prognosis Model for 28-Day Mortality in Acute-on-Chronic Liver Failure Patients. Risk Manag Healthc Policy 2020;13:3155-63. [PMID: 33402854 DOI: 10.2147/RMHP.S281999] [Reference Citation Analysis]
487 Marasco G, Alemanni LV, Colecchia A, Festi D, Bazzoli F, Mazzella G, Montagnani M, Azzaroli F. Prognostic Value of the Albumin-Bilirubin Grade for the Prediction of Post-Hepatectomy Liver Failure: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2011. [PMID: 34066674 DOI: 10.3390/jcm10092011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
488 Sun X, Mei J, Lin W, Yang Z, Peng W, Chen J, Zhang Y, Xu L, Chen M. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer 2021;21:775. [PMID: 34218801 DOI: 10.1186/s12885-021-08428-w] [Reference Citation Analysis]
489 Li P, Wu L, Li Z, Li J, Ye W, Shi Z, Xu Z, Zhu C, Ye H, Liu Z, Liang C. Spleen Radiomics Signature: A Potential Biomarker for Prediction of Early and Late Recurrences of Hepatocellular Carcinoma After Resection. Front Oncol 2021;11:716849. [PMID: 34485152 DOI: 10.3389/fonc.2021.716849] [Reference Citation Analysis]
490 Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K;  Real-life Practice Experts for HCC (RELPEC) Study Group;  HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med. 2019;8:137-146. [PMID: 30575325 DOI: 10.1002/cam4.1909] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 15.0] [Reference Citation Analysis]
491 Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:146. [PMID: 32782275 DOI: 10.1038/s41392-020-00264-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
492 Nomoto H, Morimoto N, Miura K, Watanabe S, Takaoka Y, Maeda H, Sasaki T, Koyashiki Y, Kurata H, Numao N, Isoda N, Yamamoto H. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study. BMC Gastroenterol 2020;20:427. [PMID: 33317473 DOI: 10.1186/s12876-020-01573-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
493 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Takahashi Y, Honda T, Yajima H, Uehara R, Hino N, Hirata R, Taura N, Nakao K. Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease. Biomed Rep 2020;12:89-98. [PMID: 32042417 DOI: 10.3892/br.2020.1273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
494 Samawi HH, Sim HW, Chan KK, Alghamdi MA, Lee-Ying RM, Knox JJ, Gill P, Romagnino A, Batuyong E, Ko YJ, Davies JM, Lim HJ, Cheung WY, Tam VC; CHORD Consortium. Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. Cancer Med 2018. [PMID: 29766659 DOI: 10.1002/cam4.1493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
495 Keating GM. Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol. 2017;12:243-253. [PMID: 28299600 DOI: 10.1007/s11523-017-0484-7] [Cited by in Crossref: 95] [Cited by in F6Publishing: 107] [Article Influence: 19.0] [Reference Citation Analysis]
496 Kamachi N, Shimose S, Hirota K, Koya S, Iwamoto H, Niizeki T, Shirono T, Nakano M, Hashida R, Kawaguchi T, Matuse H, Noguchi K, Koga H, Torimura T. Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma. Mol Clin Oncol 2021;14:79. [PMID: 33758660 DOI: 10.3892/mco.2021.2241] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
497 Huang F, Gao J. Modified Child-Pugh grade vs albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy. World J Gastroenterol 2020; 26(7): 749-758 [PMID: 32116422 DOI: 10.3748/wjg.v26.i7.749] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
498 Yamada S, Kaneshiro T, Yoshihisa A, Nodera M, Amami K, Nehashi T, Takeishi Y. Albumin-Bilirubin Score for Prediction of Outcomes in Heart Failure Patients Treated with Cardiac Resynchronization Therapy. J Clin Med 2021;10:5378. [PMID: 34830658 DOI: 10.3390/jcm10225378] [Reference Citation Analysis]
499 Nguyen TTH, Nguyen VH, Nguyen VH, Nguyen TL, Le VQ. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam. Cancer Control. 2019;26:1073274819865269. [PMID: 31364390 DOI: 10.1177/1073274819865269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
500 Kawashima A, Yamamoto Y, Sato M, Nakata W, Kakuta Y, Ishizuya Y, Yamaguchi Y, Yamamoto A, Yoshida T, Takayama H, Takada T, Inoue H, Okuda Y, Kato T, Hatano K, Uemura M, Nonomura N, Imamura R. FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab. Sci Rep 2021;11:21199. [PMID: 34707147 DOI: 10.1038/s41598-021-00509-x] [Reference Citation Analysis]
501 Fujita K, Nomura T, Morishita A, Oura K, Yoneyama H, Kobara H, Tsutsui K, Himoto T, Masaki T. Albumin-Bilirubin Score Differentiates Liver Fibrosis Stage and Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Virus Infection: A Retrospective Cohort Study. Am J Trop Med Hyg 2019;101:220-5. [PMID: 31115300 DOI: 10.4269/ajtmh.19-0129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
502 Kelley RK, Miksad R, Cicin I, Chen Y, Klümpen HJ, Kim S, Lin ZZ, Youkstetter J, Hazra S, Sen S, Cheng AL, El-Khoueiry AB, Meyer T, Abou-Alfa GK. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. Br J Cancer 2021. [PMID: 34621044 DOI: 10.1038/s41416-021-01532-5] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
503 Chen M, Cao J, Hu J, Topatana W, Li S, Juengpanich S, Lin J, Tong C, Shen J, Zhang B, Wu J, Pocha C, Kudo M, Amedei A, Trevisani F, Sung PS, Zaydfudim VM, Kanda T, Cai X. Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. Liver Cancer 2021;10:38-51. [PMID: 33708638 DOI: 10.1159/000512028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
504 Li L, Mo F, Hui EP, Chan SL, Koh J, Tang NLS, Yu SCH, Yeo W. The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterol 2019;19:66. [PMID: 31046687 DOI: 10.1186/s12876-019-0984-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
505 Grgurević I, Bokun T, Mustapić S, Trkulja V, Heinzl R, Banić M, Puljiz Ž, Lukšić B, Kujundžić M. Real-time two-dimensional shear wave ultrasound elastography of the liver is a reliable predictor of clinical outcomes and the presence of esophageal varices in patients with compensated liver cirrhosis. Croat Med J 2015;56:470-81. [PMID: 26526884 DOI: 10.3325/cmj.2015.56.470] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
506 Fujita K, Oura K, Tadokoro T, Nakahara M, Tani J, Morishita A, Kobara H, Tsutsui K, Himoto T, Masaki T. Prognosis of probable autoimmune hepatitis patients: a single-center study in Japan. Intern Emerg Med 2021. [PMID: 33783693 DOI: 10.1007/s11739-021-02720-0] [Reference Citation Analysis]
507 Chi CT, Lee IC, Lee RC, Hung YW, Su CW, Hou MC, Chao Y, Huang YH. Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. Cancers (Basel) 2021;13:4325. [PMID: 34503135 DOI: 10.3390/cancers13174325] [Reference Citation Analysis]
508 Al Jarroudi O, Chaabouni H, Ulusakarya A, Almohamad W, Gumus Y, Goldschmidt E, Afqir S, Morère JF. Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience. Clin Case Rep 2021;9:2162-7. [PMID: 33936657 DOI: 10.1002/ccr3.3970] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
509 Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer 2019;8:312-25. [PMID: 31768342 DOI: 10.1159/000494844] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
510 Miyamoto Y, Enomoto H, Nishikawa H, Nishimura T, Iwata Y, Nishiguchi S, Iijima H. Association of the Modified ALBI Grade With Endoscopic Findings of Gastroesophageal Varices. In Vivo 2021;35:1163-8. [PMID: 33622916 DOI: 10.21873/invivo.12364] [Reference Citation Analysis]
511 Yen FS, Lai JN, Wei JC, Chiu LT, Hwu CM, Hou MC, Hsu CC. Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis. PLoS One 2020;15:e0243783. [PMID: 33315940 DOI: 10.1371/journal.pone.0243783] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]